aspirin has been researched along with Embolism, Pulmonary in 348 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 9.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| " No significant differences in deep venous thrombosis, pulmonary embolism, and bleeding complications rates were found between aspirin and LMWH." | 9.41 | The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Gao, S; Liu, W; Meng, J; Tang, H; Wu, Y; Xiao, Y, 2023) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 9.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 9.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding." | 9.16 | Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012) |
| "To study the efficacy and safety of aspirin in prophylaxis of venous thromboembolism (VTE) after total joint arthroplasty." | 9.12 | [Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty]. ( Liu, Y; Song, F; Tian, H; Zhang, K, 2007) |
| "Among the patients with hip fracture, allocation to aspirin produced proportional reductions in pulmonary embolism of 43% (95% CI 18-60; p=0." | 9.09 | Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. ( , 2000) |
| " There were no significant differences in symptomatic pulmonary embolism, symptomatic deep vein thrombosis, 90-day mortality, or major bleeding between patients receiving low-dose or high-dose aspirin." | 9.05 | Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review. ( Azboy, I; Goswami, K; Groff, H; Parvizi, J; Vahedian, M, 2020) |
| "In a prospective randomized clinical trial involving 150 patients who underwent major abdominal surgery, acetylsalicylic acid (ASA) and dihydroergotamine (DHE) were examined either alone or in combination for their potential to prevent thromboembolism." | 9.05 | Acetylsalicylic acid in combination with dihydroergotamine for preventing thromboembolism. ( Neumann, K; Schemper, M; Zekert, F, 1982) |
| " The use of aspirin has been implicated in reducing VTE events and is potentially advantageous compared to other agents in respect to cost, access, route of administration and reduced adverse effects such as bleeding." | 9.01 | Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence. ( Fletcher, JP; Hitos, K; Seagrave, KG, 2019) |
| "A short cut review was carried out to establish whether aspirin is a useful adjunct in the treatment of acute pulmonary embolism." | 8.82 | Best evidence topic report. Aspirin in the treatment of acute pulmonary embolism. ( Ferguson, C; Lee, C, 2005) |
| "The attitude and approach of orthopedic community for minimizing venous thromboembolism (VTE) has evolved over the last decade with the trend toward use of aspirin (and mechanical modalities) in lieu of aggressive anticoagulation." | 8.12 | Time to Venous Thromboembolism Events Following Total Hip Arthroplasty: A Comparison Between Aspirin and Warfarin. ( Goel, R; Ludwick, L; Parvizi, J; Shohat, N, 2022) |
| "The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty." | 7.96 | Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020) |
| " Aspirin has been considered a safe and cost-effective prophylaxis for venous thromboembolism (VTE), and there have been some reports about the incidence of PTE (0%-0." | 7.96 | Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. ( Hirakawa, K; Mihara, M; Nakura, N; Ochiai, S; Saito, A; Takayanagi, S; Tamaki, Y, 2020) |
| "Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)." | 7.88 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018) |
| "The present study aimed to explore the influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism (APE) in rats." | 7.85 | Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism. ( Cai, D; Jiang, H; Kuang, J; Shi, Y; Wang, L; Yang, R; Yang, W; Ying, R; Zhang, Z, 2017) |
| "ESSENTIALS: We audited venous thromboembolism (VTE) in Achilles injuries after the use of prophylactic aspirin." | 7.83 | Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit. ( Beasley, R; Braithwaite, I; Dunbar, L; Eathorne, A; Weatherall, M, 2016) |
| "To explore the intervention of aspirin and the changes of CX3CL1 and its receptor CX3CR1 in a rat model of acute pulmonary embolism (APE)." | 7.79 | [Effects of aspirin on CX3CL1 and CX3CR1 in acute pulmonary embolism rats]. ( Jiang, HF; Sun, C; Wang, LC; Yang, RH, 2013) |
| "Although this study was performed on a relatively small number of patients undergoing total hip arthroplasty in conjunction with aspirin prophylaxis for postoperative pulmonary embolism, several important points are noted: the use of pre- and postoperative lung perfusion scanning can eliminate a 15% rate of false-positive diagnosis of pulmonary embolism, and pulmonary embolism occurred in approximately 8% of patients undergoing total hip arthroplasty in conjunction with aspirin prophylaxis, without fatality." | 7.66 | Aspirin prophylaxis for pulmonary embolism following total hip arthroplasty. An incidence study. ( Dorr, LD; Ranawat, CS; Schneider, R; Stulberg, BN, 1982) |
| "The efficacy of two antithrombotic regimens, combined dextran and aspirin and combined dextran and warfarin, was analyzed by comparing the incidence of thromboembolism following total hip replacement in two groups of similar patients." | 7.65 | Thromboembolism following total hip-replacement arthroplasty. The efficicy of dextran-aspirin and dextran-warfarin in prophylaxis. ( Lachiewicz, P; Salvati, EA, 1976) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 6.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| "However, more recently, the rate of deep vein thrombosis (DVT) has been reported to be approximately 10%." | 6.80 | Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial. ( Alaia, MJ; Garofolo, G; Jazrawi, LM; Kaye, ID; Martinez, A; Patel, DN; Strauss, EJ, 2015) |
| "5, and aspirin was administered at a dosage of 75 to 325 mg/d." | 6.52 | Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. ( Chen, KP; Zhang, JT; Zhang, S, 2015) |
| "Is it better to continue treatment of deep venous thrombosis or pulmonary embolism with LMWH or switch to an oral anticoagulant? What is the optimal duration of treatment? To answer these questions, we conducted a review of the literature using the standard Prescrire methodology." | 6.49 | Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. ( , 2013) |
| " The aim of this study is to determine if discontinued use of outpatient IPCDs is safe and does not increase the rate of VTE or any other related complications in patients following TKA." | 5.72 | Discontinued Use of Outpatient Portable Intermittent Pneumatic Compression Devices May Be Safe for Venous Thromboembolism Prophylaxis in Primary Total Knee Arthroplasty Using Low-Dose Aspirin. ( Lajam, C; Lygrisse, K; Macaulay, W; Meftah, M; Schwarzkopf, R; Slover, J; Tang, A; Zak, S, 2022) |
| "In this pilot study, there were no significant differences in any outcome assessed; however, recurrent thromboembolic events and minor bleeding events occurred numerically less frequently in the rivaroxaban plus aspirin group." | 5.69 | Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban. ( Erika, MH; Jaime, GC; Maximiliano, CL, 2023) |
| "In patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality." | 5.69 | Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. ( Bosse, MJ; Carlini, AR; Castillo, RC; Degani, Y; Firoozabadi, R; Frey, KP; Goldhaber, SZ; Haut, ER; Marvel, D; O'Hara, NN; O'Toole, RV; Obremskey, W; Scharfstein, DO; Slobogean, GP; Stein, DM; Sudini, K; Taylor, TJ, 2023) |
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 5.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "We assessed the incidence of fatal pulmonary embolism (PE) and all-cause mortality following elective primary total knee replacement (TKR) with a standardised multi-modal prophylaxis regime in a large teaching district general hospital." | 5.46 | Fatal pulmonary embolism following elective total knee replacement using aspirin in multi-modal prophylaxis - A 12year study. ( Bayley, E; Bhamber, N; Howard, P; Quah, C, 2017) |
| "The rate of surgical site infection was similar between the aspirin group and the warfarin group (1." | 5.43 | Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016) |
| " No significant differences in deep venous thrombosis, pulmonary embolism, and bleeding complications rates were found between aspirin and LMWH." | 5.41 | The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Gao, S; Liu, W; Meng, J; Tang, H; Wu, Y; Xiao, Y, 2023) |
| "Inflammation contributes to acute pulmonary embolism (APE)." | 5.39 | Effects of aspirin on the ERK and PI3K/Akt signaling pathways in rats with acute pulmonary embolism. ( Jiang, R; Wang, L; Wu, J; Wu, Y; Yang, R; Zhang, W; Zhi, Y, 2013) |
| "The rate of pulmonary embolism was 0." | 5.37 | The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. ( Charman, SC; Gregg, PJ; Jameson, SS; Reed, MR; van der Meulen, JH, 2011) |
| "Aspirin was the principle chemoprophylactic agent for 3473 consecutive patients having total knee arthroplasty." | 5.33 | The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. ( Lonner, JH; Lotke, PA, 2006) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 5.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "Aspirin (650 mg) was given the night prior to surgery and continued at that dose twice per day." | 5.28 | Aspirin prophylaxis and surveillance of pulmonary embolism and deep vein thrombosis in total hip arthroplasty. ( Jones, K; Lachiewicz, PF; McCardel, BR, 1990) |
| "Picotamide did not inhibit the formation of TxB2 in serum at any of the doses tested (100 to 750 mg/kg i." | 5.28 | Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. ( Alberti, P; Corona, C; Gresele, P; Nenci, GG, 1990) |
| "Pretreatment with methysergide 3 mg/kg also significantly (p less than 0." | 5.27 | The effects of aspirin and methysergide on responses to clot-induced pulmonary embolism. ( Cragg, DB; Forrest, JB; Todd, MH, 1983) |
| "The aspirin-treated dogs had greater resolution of pulmonary arterial proliferative disease, and prednisolone-treated dogs had the lesser resolution." | 5.27 | Pulmonary thromboembolism during therapy of dirofilariasis with thiacetarsamide: modification with aspirin or prednisolone. ( Keith, JC; Rawlings, CA; Schaub, RG, 1983) |
| "Aspirin was administered in the recovery room and continued 600 mg twice a day until discharge." | 5.27 | Activity, air boots, and aspirin as thromboembolism prophylaxis in knee arthroplasty. A multiple regimen approach. ( Clayton, ML; Thompson, TR, 1987) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 5.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding." | 5.16 | Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012) |
| "The study reports higher risks of venous thromboembolism, pulmonary embolism, and overall mortality for the patients receiving aspirin before undergoing." | 5.12 | Comparison between use of direct oral anticoagulants and aspirin for risk of thromboembolism complications in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis. ( Cai, JY; Cao, YQ; Cui, CM; Min, JK; Zhang, LY, 2021) |
| "To study the efficacy and safety of aspirin in prophylaxis of venous thromboembolism (VTE) after total joint arthroplasty." | 5.12 | [Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty]. ( Liu, Y; Song, F; Tian, H; Zhang, K, 2007) |
| "Among the patients with hip fracture, allocation to aspirin produced proportional reductions in pulmonary embolism of 43% (95% CI 18-60; p=0." | 5.09 | Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. ( , 2000) |
| " There were no significant differences in symptomatic pulmonary embolism, symptomatic deep vein thrombosis, 90-day mortality, or major bleeding between patients receiving low-dose or high-dose aspirin." | 5.05 | Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review. ( Azboy, I; Goswami, K; Groff, H; Parvizi, J; Vahedian, M, 2020) |
| "In a prospective randomized clinical trial involving 150 patients who underwent major abdominal surgery, acetylsalicylic acid (ASA) and dihydroergotamine (DHE) were examined either alone or in combination for their potential to prevent thromboembolism." | 5.05 | Acetylsalicylic acid in combination with dihydroergotamine for preventing thromboembolism. ( Neumann, K; Schemper, M; Zekert, F, 1982) |
| " The use of aspirin has been implicated in reducing VTE events and is potentially advantageous compared to other agents in respect to cost, access, route of administration and reduced adverse effects such as bleeding." | 5.01 | Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence. ( Fletcher, JP; Hitos, K; Seagrave, KG, 2019) |
| "To evaluate efficacy and safety of oral anticoagulant regimens and aspirin for extended venous thromboembolism (VTE) treatment." | 5.01 | Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. ( Büller, HR; Cameron, C; Carrier, M; Castellucci, LA; van Es, N; Wang, KL, 2019) |
| ": Rivaroxaban, a direct oral anticoagulant, is widely used for the treatment of venous thromboembolism (VTE) in adult patients." | 5.01 | Rivaroxaban and the EINSTEIN clinical trial programme. ( Bauersachs, R; Cohen, AT, 2019) |
| "Aspirin, both alone and in multimodal approaches to thromboprophylaxis, confers a low rate of VTE, with a low risk of major bleeding complications." | 4.93 | Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( An, VV; Bruce, WJ; Levy, YD; Phan, K, 2016) |
| "Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism." | 4.90 | Update on pharmacologic therapy for pulmonary embolism. ( Aronow, WS; Harikrishnan, P; Palaniswamy, C, 2014) |
| "A short cut review was carried out to establish whether aspirin is a useful adjunct in the treatment of acute pulmonary embolism." | 4.82 | Best evidence topic report. Aspirin in the treatment of acute pulmonary embolism. ( Ferguson, C; Lee, C, 2005) |
| "Anticoagulant therapy is indicated during pregnancy for the prevention and treatment of VTE; for the prevention and treatment of systemic embolism in patients with mechanical heart valves; and, often in combination with aspirin, for the prevention of pregnancy loss in women with APLAs or thrombophilia and previous pregnancy losses." | 4.81 | Use of antithrombotic agents during pregnancy. ( Ginsberg, JS; Greer, I; Hirsh, J, 2001) |
| " The purpose of this study was to define the efficacy and safety of the agents that are currently used for prophylaxis against deep venous thrombosis -- namely, low-molecular-weight heparin, warfarin, aspirin, low-dose heparin, and pneumatic compression." | 4.80 | A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. ( Brookenthal, KR; Fitzgerald, RH; Freedman, KB; Lonner, JH; Williams, S, 2000) |
| "Most randomised trials of anticoagulant therapy for suspected acute myocardial infarction have been small and, in some, aspirin and fibrinolytic therapy were not used routinely." | 4.79 | Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. ( Appleby, P; Baigent, C; Collins, R; Flather, M; Godwin, J; MacMahon, S; Mortensen, S; Peto, R; Remvig, L; Yusuf, S, 1996) |
| "Aspirin may be effective at preventing venous thromboembolism following total knee arthroplasty (TKA) or total hip arthroplasty (THA)." | 4.31 | Aspirin for Venous Thromboembolic Prophylaxis Following Total Hip and Total Knee Arthroplasty: An Analysis of Safety and Efficacy Accounting for Surgeon Selection Bias. ( Christ, AB; Heckmann, ND; Lieberman, JR; Mayfield, CK; Oakes, DA; Piple, AS; Richardson, MK; Wang, JC, 2023) |
| "The attitude and approach of orthopedic community for minimizing venous thromboembolism (VTE) has evolved over the last decade with the trend toward use of aspirin (and mechanical modalities) in lieu of aggressive anticoagulation." | 4.12 | Time to Venous Thromboembolism Events Following Total Hip Arthroplasty: A Comparison Between Aspirin and Warfarin. ( Goel, R; Ludwick, L; Parvizi, J; Shohat, N, 2022) |
| " The incidence of VTE and hematoma formation was evaluated and compared between patients who received aspirin versus enoxaparin or heparin." | 4.12 | Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures? ( Du, JY; Metcalf, KB; Ochenjele, G, 2022) |
| "The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty." | 3.96 | Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020) |
| " Aspirin has been considered a safe and cost-effective prophylaxis for venous thromboembolism (VTE), and there have been some reports about the incidence of PTE (0%-0." | 3.96 | Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. ( Hirakawa, K; Mihara, M; Nakura, N; Ochiai, S; Saito, A; Takayanagi, S; Tamaki, Y, 2020) |
| "The results of this study clearly show that aspirin, as part of a multimodal thromboprophylactic regime, is an effective and safe regime in preventing venous thromboembolism with respect to risk of deep vein thrombosis or pulmonary embolism when compared to LMWH." | 3.91 | Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases. ( Best, AJ; Chatterji, U; Ghosh, A; Rudge, SJ, 2019) |
| "The aims of this study were to compare the efficacy of two agents, aspirin and warfarin, for the prevention of venous thromboembolism (VTE) after simultaneous bilateral total knee arthroplasty (SBTKA), and to elucidate the risk of VTE conferred by this procedure compared with unilateral TKA (UTKA)." | 3.88 | Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin ( Fleischman, AN; Goel, R; Higuera, C; Huang, R; Parvizi, J; Rothman, RH; Sterbis, E; Tan, T, 2018) |
| "Aspirin and unfractionated heparin (UH) are accepted options for venous thromboembolism (VTE) prophylaxis after total joint arthroplasty (TJA)." | 3.88 | The Role of Aspirin and Unfractionated Heparin Combination Therapy Immediately After Total Hip and Knee Arthroplasty. ( Karadsheh, MS; Koueiter, DM; Mells, A; Siljander, MP; Sobh, AH, 2018) |
| "Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)." | 3.88 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018) |
| "Using data from the Reduced-Dose Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism (EINSTEIN-CHOICE) trial, this study assessed cost impact of continued anticoagulation therapy with rivaroxaban vs aspirin." | 3.88 | Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. ( Ashton, V; Beyer-Westendorf, J; Crivera, C; Haskell, L; Laliberté, F; Lefebvre, P; Lejeune, D; Lensing, AWA; Levitan, B; Prandoni, P; Prins, MH; Schein, J; Wells, PS; Xiao, Y; Yuan, Z; Zhao, Q, 2018) |
| "The present study aimed to explore the influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism (APE) in rats." | 3.85 | Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism. ( Cai, D; Jiang, H; Kuang, J; Shi, Y; Wang, L; Yang, R; Yang, W; Ying, R; Zhang, Z, 2017) |
| "There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives." | 3.85 | Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017) |
| "ESSENTIALS: We audited venous thromboembolism (VTE) in Achilles injuries after the use of prophylactic aspirin." | 3.83 | Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit. ( Beasley, R; Braithwaite, I; Dunbar, L; Eathorne, A; Weatherall, M, 2016) |
| "This study's purpose was to present our institution's experience with the use of a risk stratification protocol for venous thromboembolism (VTE) prophylaxis in joint arthroplasty in which "routine" risk patients receive a mobile compression device in conjunction with aspirin and "high"-risk patients receive warfarin for thromboprophylaxis." | 3.83 | The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty. ( Barrack, RL; Clohisy, JC; Johnson, SR; Keeney, JA; Nam, D; Nunley, RM, 2016) |
| " We compared the incidence of fatal pulmonary embolism in patients undergoing elective primary total hip arthroplasty (THA) between those receiving aspirin, warfarin and low molecular weight heparin (LMWH) for the chemical component of a multi-modal thromboprophylaxis regime." | 3.83 | Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study. ( Bayley, E; Bhamber, NS; Brown, S; Howard, PW, 2016) |
| " In murine thrombosis models, nstpbp5185 significantly prolonged the latent period in triggering platelet plug formation in mesenteric and FeCl3-induced thrombi formation, and increased the survival rate in pulmonary embolism model with less bleeding than aspirin." | 3.83 | A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models. ( Hsu, MT; Huang, SW; Huang, TF; Kuo, HL; Kuo, SC; Lien, JC; Lin, SW; Peng, HC; Tseng, YJ, 2016) |
| "01) the rate of transfusion, units of packed red blood cells, hemoglobin drop, and hematocrit drop compared to aspirin in both unilateral and bilateral TKA patients, without significantly decreasing venous thromboembolism events (aspirin: 3 pulmonary embolisms and 4 deep venous thrombosis; Lovenox: 3 pulmonary embolisms and 2 deep venous thrombosis)." | 3.83 | Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin. ( Hall, KE; Nakasone, CK; Radzak, KN; Wages, JJ, 2016) |
| "We sought to determine the frequency of thromboembolic events (deep vein thrombosis [DVT] and symptomatic pulmonary embolism [PE]) associated with the periacetabular osteotomy in in patients receiving aspirin and mechanical compression prophylaxis." | 3.80 | Screening for deep vein thrombosis after periacetabular osteotomy in adult patients: is it necessary? ( Bloemke, AD; Clohisy, JC; Duncan, ST; Polkowski, GG; Schoenecker, PL, 2014) |
| "To explore the intervention of aspirin and the changes of CX3CL1 and its receptor CX3CR1 in a rat model of acute pulmonary embolism (APE)." | 3.79 | [Effects of aspirin on CX3CL1 and CX3CR1 in acute pulmonary embolism rats]. ( Jiang, HF; Sun, C; Wang, LC; Yang, RH, 2013) |
| "Our institution has used a thromboprophylaxis regimen consisting of inpatient enoxaparin and outpatient aspirin for patients at standard risk for venous thrombosis after hip and knee arthroplasty." | 3.78 | Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. ( Anderson, BJ; Bradbury, TL; Erens, GA; Hamilton, SC; Roberson, JR; Whang, WW, 2012) |
| " Deep vein thrombosis prophylaxis consisted of oral enteric-coated aspirin, pneumatic calf compression pumps, and early ambulation in all patients unless medically contraindicated." | 3.77 | Thromboembolic events are uncommon after open treatment of proximal humerus fractures using aspirin and compression devices. ( Abboud, JA; Bassora, R; Warrender, WJ; Widmer, BJ, 2011) |
| "We studied 4253 patients undergoing primary joint replacement between November 2002 and November 2007, of whom 4060 received aspirin only as chemical prophylaxis; 46 were mistakenly given low molecular weight heparin initially, which was stopped and changed to aspirin; 136 received no chemoprophylaxis and 11 patients received warfarin because of a previous history of pulmonary embolism." | 3.75 | The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients. ( Beverland, DE; Cusick, LA, 2009) |
| "Our objective of the study was to address the question: "What is the efficacy of a deep venous thrombosis (DVT) and pulmonary embolus prophylaxis protocol after total knee arthroplasty (TKA) in which low-risk patients had only aspirin and mechanical devices for prophylaxis?" A multimodal approach to DVT prophylaxis using aspirin as the primary mode of chemoprophylaxis was successful in preventing DVT-related morbidity and mortality in 312 consecutive TKAs performed in low-risk patients." | 3.74 | Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. ( Callaghan, JJ; Hoballah, JJ; Liu, SS; Warth, LC; Wells, CW, 2008) |
| " Pulmonary thromboembolism-induced Evans blue dye leakage was also reduced significantly by aspirin (5 mg/kg), but PGE1 (170 micrograms/kg) showed a tendency to potentiate the edematogenic response." | 3.69 | Anti-inflammatory effects of beraprost sodium, a stable analogue of PGI2, and its mechanisms. ( Annoh, S; Koike, H; Nishio, S; Ueno, Y, 1997) |
| "Although this study was performed on a relatively small number of patients undergoing total hip arthroplasty in conjunction with aspirin prophylaxis for postoperative pulmonary embolism, several important points are noted: the use of pre- and postoperative lung perfusion scanning can eliminate a 15% rate of false-positive diagnosis of pulmonary embolism, and pulmonary embolism occurred in approximately 8% of patients undergoing total hip arthroplasty in conjunction with aspirin prophylaxis, without fatality." | 3.66 | Aspirin prophylaxis for pulmonary embolism following total hip arthroplasty. An incidence study. ( Dorr, LD; Ranawat, CS; Schneider, R; Stulberg, BN, 1982) |
| " In the presence of thrombophlebitis, phenylbutazone (Butazolidin) is used." | 3.65 | A multifaceted approach to prevention of thromboembolism: a report of 529 cases. ( Brady, LP, 1977) |
| "The efficacy of two antithrombotic regimens, combined dextran and aspirin and combined dextran and warfarin, was analyzed by comparing the incidence of thromboembolism following total hip replacement in two groups of similar patients." | 3.65 | Thromboembolism following total hip-replacement arthroplasty. The efficicy of dextran-aspirin and dextran-warfarin in prophylaxis. ( Lachiewicz, P; Salvati, EA, 1976) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 2.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| " GI bleeding was equally prevalent between the 2 dosing regimens, so patients need to be informed of this risk regardless of the ASA dose." | 2.84 | A Comparison of Two Dosing Regimens of ASA Following Total Hip and Knee Arthroplasties. ( Chen, AF; Feldstein, MJ; Hozack, WJ; Low, SL; Woodward, LA, 2017) |
| "Our primary outcomes were pulmonary embolism (PE), symptomatic DVT, asymptomatic DVT, and all-cause mortality." | 2.82 | Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. ( Badariotti, G; Chahla, J; Perrotta, C; Ramos, J, 2022) |
| "However, more recently, the rate of deep vein thrombosis (DVT) has been reported to be approximately 10%." | 2.80 | Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial. ( Alaia, MJ; Garofolo, G; Jazrawi, LM; Kaye, ID; Martinez, A; Patel, DN; Strauss, EJ, 2015) |
| "Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer diagnosis) were prospectively evaluated, secondary end points of the trial." | 2.73 | Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM; Zee, RY, 2007) |
| "The aspirin and warfarin treatment groups were compared by size and location of venographically revealed clots and changes in ventilation perfusion scans." | 2.68 | Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. ( Ecker, ML; Keenan, AM; Kelley, MA; Lotke, PA; Meranze, S; Palevsky, H; Steinberg, ME, 1996) |
| "Aspirin was used as prophylaxis against thromboembolism during the first half of the study and adjusted-dose warfarin during the second half." | 2.68 | The frequency of venous thrombosis in cemented and non-cemented hip arthroplasty. ( Bourne, R; Bullas, R; Feeny, D; Laupacis, A; Rankin, R; Rorabeck, C; Tugwell, P; Vellet, AD; Wong, C, 1996) |
| "The incidence of pulmonary embolism on lung scan was 12% with epidural anesthesia and 9% with general anesthesia." | 2.68 | Randomized trial of epidural versus general anesthesia: outcomes after primary total knee replacement. ( Ganz, SB; Go, G; Haas, SB; Insall, J; Laskin, RS; Ranawat, CS; Sharrock, NE; Williams-Russo, P; Windsor, RE, 1996) |
| "The incidence of pulmonary embolism (PE) in all trials combined was low, with seven cases in 3818 participants." | 2.66 | Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. ( Badariotti, G; Chahla, J; Perrotta, C; Ramos, J, 2020) |
| "Proximal vein thrombosis or pulmonary embolism occurred in 6 patients (9." | 2.66 | A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. ( Gent, M; Hirsh, J; Jay, RM; Julian, DH; Levine, M; Powers, PJ; Turpie, AG, 1989) |
| "Aspirin was able to reduce the postoperative increase in circulating platelet aggregates, platelet factor 4 and beta-thromboglobulin observed in control group." | 2.66 | Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. ( Alfaro, MJ; Páramo, JA; Rocha, E, 1986) |
| " Increasing the heparin dosage postoperatively to 3 X 7500 IU/24 h effectively prevented the incidence of thrombosis by reducing it to 11% in these high-risk patients." | 2.64 | [Heparin in the prevention of thromboembolism after elective hip-joint operations (author's transl)]. ( Schöndorf, TH, 1978) |
| "The frequency in letal pulmonary embolism at the I." | 2.64 | [Thrombosis, embolism and aggregation inhibitors in surgery]. ( Zekert, F, 1976) |
| "A symptomatic pulmonary embolism (PE) after total joint arthroplasty has been described as a "never event." | 2.55 | Pulmonary Embolism Rates Following Total Hip Arthroplasty With Prophylactic Anticoagulation: Some Pulmonary Emboli Cannot Be Avoided. ( Cheng, V; Cote, MP; Lieberman, JR, 2017) |
| "5, and aspirin was administered at a dosage of 75 to 325 mg/d." | 2.52 | Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. ( Chen, KP; Zhang, JT; Zhang, S, 2015) |
| "Is it better to continue treatment of deep venous thrombosis or pulmonary embolism with LMWH or switch to an oral anticoagulant? What is the optimal duration of treatment? To answer these questions, we conducted a review of the literature using the standard Prescrire methodology." | 2.49 | Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. ( , 2013) |
| "Sudden cardiac death is a leading cause of death in Europe." | 2.46 | [Thrombolysis during cardio-pulmonary resuscitation]. ( Böttiger, BW; Padosch, SA; Spöhr, F; Teschendorf, P; Wetsch, WA, 2010) |
| "Systolic heart failure is a common syndrome whose incidence is expected to increase." | 2.45 | Systolic heart failure: a prothrombotic state. ( Büller, HR; de Peuter, OR; Kamphuisen, PW; Kok, WE; Torp-Pedersen, C, 2009) |
| "Fatal pulmonary embolism is estimated to occur in nearly 1% of these women." | 2.44 | WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. ( D'Angelo, A; Mol, B; Oates-Whitehead, RM, 2007) |
| "Recently, the thrombophilias have been revealed as risk factors for severe preeclampsia, abruptio placentae, fetal growth retardation, abortion and still birth as well." | 2.42 | [Anticoagulation and antiaggregation during pregnancy]. ( Biasiutti, FD; Strebel, JK, 2003) |
| "Fatal pulmonary embolism is estimated to occur in nearly 1% of these women." | 2.42 | Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. ( D'Angelo, A; Mol, B; Oates-Whitehead, RM, 2003) |
| "Aspirin has also demonstrated a potential ability to reduce the risk of deep venous thrombosis and pulmonary embolism." | 2.41 | An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I. ( Moyad, MA, 2001) |
| "Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid)." | 2.40 | Triflusal. ( Goa, KL; McNeely, W, 1998) |
| "Aspirin has been disappointing." | 2.38 | Deep venous thrombosis and pulmonary emboli: etiology, medical treatment, and prophylaxis. ( Coffman, JD, 1989) |
| "The results of treatment of the fat embolism syndrome should improve if there is a realization that even relatively uncomplicated fractures of the extremities cause significant metabolic, platelet, coagulation and pulmonary changes." | 2.36 | Fat embolism syndrome: traumatic coagulopathy with respiratory distress. ( Shier, MR; Wilson, RF, 1980) |
| "After the procedure, deep vein thrombosis (DVT) was a commonly diagnosed complication (3." | 1.91 | Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention. ( Agala, C; Caruso, DM; Duchesneau, E; Farber, M; Kindell, DG; Marston, WA; Marulanda, K; McGinigle, KL, 2023) |
| "The incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) after total joint arthroplasty (TJA) procedures are lower in Asian populations than in Caucasian populations." | 1.91 | Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population. ( Chang, WL; Chen, CF; Chen, WM; Chou, TA; Pai, FY; Tsai, SW; Wu, PK, 2023) |
| " The aim of this study is to determine if discontinued use of outpatient IPCDs is safe and does not increase the rate of VTE or any other related complications in patients following TKA." | 1.72 | Discontinued Use of Outpatient Portable Intermittent Pneumatic Compression Devices May Be Safe for Venous Thromboembolism Prophylaxis in Primary Total Knee Arthroplasty Using Low-Dose Aspirin. ( Lajam, C; Lygrisse, K; Macaulay, W; Meftah, M; Schwarzkopf, R; Slover, J; Tang, A; Zak, S, 2022) |
| "The current rates of deep vein thrombosis (DVT) and pulmonary embolism (PE) at our institution following hip or knee arthroplasty or hip fracture surgery are 1." | 1.56 | Incidence of venous thromboembolism after total hip, total knee and hip fracture surgery at Waitemata District Health Board following a peer-reviewed audit. ( Andrew, P; Farrington, B; Lawes, CM; Merriman, E; Millar, JS; Misur, P; Walker, M, 2020) |
| "Incidence of postoperative deep venous thrombosis (DVT), pulmonary embolism (PE), bleeding-related complications, postoperative anaemia, and transfusion were identified at 2 weeks, 30 days, 6 weeks, and 90 days." | 1.56 | Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? ( Amanatullah, DF; Bala, A; Burk, DR; Goodman, SB; Huddleston, JI; Maloney, WJ; Murasko, MJ, 2020) |
| "Funded studies reported less pulmonary embolisms, fewer events of major bleeding, and significantly less 90-day mortality compared with nonfunded studies." | 1.48 | Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. ( Azboy, I; Groff, H; Parvizi, J, 2018) |
| "We assessed the incidence of fatal pulmonary embolism (PE) and all-cause mortality following elective primary total knee replacement (TKR) with a standardised multi-modal prophylaxis regime in a large teaching district general hospital." | 1.46 | Fatal pulmonary embolism following elective total knee replacement using aspirin in multi-modal prophylaxis - A 12year study. ( Bayley, E; Bhamber, N; Howard, P; Quah, C, 2017) |
| "The incidence of symptomatic deep vein thrombosis and pulmonary embolism was evaluated." | 1.43 | Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis. ( Chen, AF; Heller, S; Parvizi, J; Secrist, E; Shahi, A, 2016) |
| "The rate of surgical site infection was similar between the aspirin group and the warfarin group (1." | 1.43 | Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016) |
| "Incidences of symptomatic deep vein thrombosis (DVT) and PE, and major or minor bleeding complications were evaluated." | 1.42 | Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients. ( Cho, KJ; Fang, R; Kim, TK; Kim, YH; Na, YG, 2015) |
| "Prophylaxis for pulmonary embolism (PE) after total joint arthroplasty (TJA) presents the clinical dilemma of balancing the risk of postoperative thrombotic risk and anticoagulation-related complications such as bleeding, hematoma formation, and infection." | 1.40 | Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors. ( Arnold, WV; Huang, R; Parvizi, J; Raphael, IJ; Rothman, RH, 2014) |
| "Aspirin use was associated with a marginally significant reduction in incidence of VTEs within 2 years of diagnosis, HR 0." | 1.40 | Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. ( Lavie, O; Leviov, M; Rennert, G; Rennert, HS; Sagi, S; Shai, A, 2014) |
| "Lenalidomide has significant antimyeloma activity but it is associated with a significant risk of venous thromboembolism (VTE)." | 1.39 | Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. ( Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kanelias, N; Kastritis, E; Kostouros, E; Politou, M; Roussou, M; Terpos, E, 2013) |
| "Inflammation contributes to acute pulmonary embolism (APE)." | 1.39 | Effects of aspirin on the ERK and PI3K/Akt signaling pathways in rats with acute pulmonary embolism. ( Jiang, R; Wang, L; Wu, J; Wu, Y; Yang, R; Zhang, W; Zhi, Y, 2013) |
| "Prophylaxis for pulmonary embolism (PE) prevention in total knee arthroplasty remains controversial." | 1.38 | Pulmonary embolism prophylaxis in more than 30,000 total knee arthroplasty patients: is there a best choice? ( Bini, SA; Inacio, MC; Khatod, M; Paxton, EW, 2012) |
| "270 patients (93 with deep vein thrombosis (DVT) or pulmonary embolism (PE), and 177 with non-haemorrhagic stroke (cerebrovascular accident (CVA)) admitted between January 2006 and December 2010 with a discharge diagnosis of either DVT, PE or CVA, who had LAC and antiphospholipid antibodies measured within 6 months from their index admission." | 1.38 | High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study. ( Broder, A; Putterman, C; Tobin, JN, 2012) |
| "The rate of VTE, pulmonary embolism, proximal deep vein thrombosis (DVT) and distal DVT was 1." | 1.38 | Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. ( Esposito, A; Gesell, M; Gonzalez Della Valle, A; Ma, Y; Memtsoudis, SG; Vulcano, E, 2012) |
| "The rate of pulmonary embolism was 0." | 1.37 | The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. ( Charman, SC; Gregg, PJ; Jameson, SS; Reed, MR; van der Meulen, JH, 2011) |
| "The results of pulmonary embolism treatment with streptase in 76 patients are discussed." | 1.35 | [The efficacy of alteplase in pulmonary embolism treatment]. ( Abramov, AS; Beskaeva, LM; Fineshin, IN; Gruzdev, AK; Malinovskiĭ, NN; Nikerov, KIu; Sal' nikov, DV, 2008) |
| "Deep venous thrombosis (DVT) and pulmonary embolism (PE) cause significant morbidity and mortality in orthopaedic surgical practice, although the incidence following surgery to the lumbosacral spine is less than following lower limb surgery." | 1.35 | Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients. ( Craig, N; Nicol, M; Sun, Y; Wardlaw, D, 2009) |
| " At the antithrombotic dosage they were free from prohemorrhagic side effect at variance with acetylsalicylic acid used as reference drug." | 1.34 | Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis. ( Ballabeni, V; Barocelli, E; Bertoni, S; Bruni, R; Impicciatore, M; Tognolini, M, 2007) |
| "Twenty patients in each group had deep venous thrombosis (7% and 5." | 1.34 | Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol. ( Anderson, J; Beksaç, B; González Della Valle, A; Salvato, EA; Sculco, TP; Sharrock, NE, 2007) |
| "Clinically symptomatic deep venous thrombosis was detected in association with four (0." | 1.34 | Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. ( Boutary, M; Dorr, LD; Gendelman, V; Long, WT; Maheshwari, AV; Wan, Z, 2007) |
| "Nonfatal pulmonary embolisms were diagnosed in 17 (0." | 1.33 | Thromboembolic disease prophylaxis in total hip arthroplasty. ( Goswami, A; Sarmiento, A, 2005) |
| "Aspirin was the principle chemoprophylactic agent for 3473 consecutive patients having total knee arthroplasty." | 1.33 | The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. ( Lonner, JH; Lotke, PA, 2006) |
| "Though her hemoptysis improved, respiratory failure suddenly worsened." | 1.33 | [A case of acute exacerbation of chronic pulmonary thromboembolism with essential thrombocythemia during treatment for hemoptysis]. ( Abe, T; Haraguchi, M; Hayashi, M; Ito, K; Nakajima, H; Sakagami, T; Tsutsui, N, 2006) |
| "Nitroaspirin has shown a number of significant advantages over the presently available antiplatelet agents; however, only clinical studies will say whether nitroaspirin represents a step forward in antithrombotic treatment." | 1.32 | NCX4016: a novel antithrombotic agent. ( Gresele, P; Mezzasoma, AM; Momi, S, 2003) |
| "The prevalence of all VTE, proximal deep vein thrombosis (PDVT), and pulmonary embolism (PE) after 21 days were 40%, 18%, and 12%, increasing to 63%, 30%, and 20% in patients with Barthel indices (BI) of < or =9 2 days after stroke (BI-2< or =9)." | 1.32 | Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. ( Coshall, C; Hunt, BJ; Kelly, J; Lewis, RR; Moody, A; Rudd, A, 2004) |
| "Two (2." | 1.31 | Isolated internal jugular vein thrombosis: risk factors and natural history. ( Deitcher, SR; Sheikh, MA; Topoulos, AP, 2002) |
| "Thirty-nine patients with deep vein thrombosis, 28 with arteriosclerosis obliterans, and 10 with pulmonary embolism were the subjects of this study." | 1.31 | Clinical assessment of vascular thrombosis using indium-111 platelet scintigraphy. ( Morimoto, Y; Mukai, T; Okada, M; Sugimoto, T, 2000) |
| "When fluorescein sodium was given at 10 microg/kg, PMC (20 microg/g) delayed occlusion time by about 1." | 1.31 | Antithrombotic effect of PMC, a potent alpha-tocopherol analogue on platelet plug formation in vivo. ( Hsiao, G; Lee, YM; Sheu, JR; Yen, MH, 2002) |
| "Vapiprost did not inhibit the primary aggregation or ATP release of human platelets stimulated with adenosine 5'-diphosphate (ADP), epinephrine (Epi) or platelet activating factor (PAF), but inhibited the secondary aggregation stimulated with those agonists at an IC50 of less than 1." | 1.30 | The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. ( Hiraishi, S; Horie, S; Ishii, H; Kazama, M; Kizaki, K; Kurusu, O; Nakahara, T; Noritake, S; Satoh, M; Yamada, M, 1997) |
| "The paper deals with fatal pulmonary embolism in patients treated at STOCER after spinal injuries, frequently with neurological impairment." | 1.30 | [Pulmonary embolism as one cause of death after spinal injury--the role of clexane]. ( Jagodziński, K; Kiwerski, JE; Krasuski, M; Krzyzosiak, L, 1998) |
| "Deep venous thrombosis was diagnosed after seven procedures (0." | 1.30 | Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. ( Goswami, AD; Sarmiento, A, 1999) |
| "This difference in asymptomatic pulmonary embolism between the two groups was statistically significant." | 1.29 | Pneumatic compression or aspirin prophylaxis against thromboembolism in total hip arthroplasty. ( Holleman, JB; Kelley, S; Klein, JA; Lachiewicz, PF, 1996) |
| "The risk of death from pulmonary embolism was similarly diminished in the group that received warfarin." | 1.28 | Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes. ( Heit, JA; Ilstrup, DM; Mohr, DN; Morrey, BF; Silverstein, MD, 1992) |
| "Symptomatic pulmonary embolism occurred in 1." | 1.28 | The significance of calf thrombi after total knee arthroplasty. ( Becker, MW; Haas, SB; Insall, JN; Tribus, CB; Windsor, RE, 1992) |
| "We conclude that, in experimental pulmonary embolism, structurally different cyclooxygenase inhibitors aggravate pulmonary hypertension and deteriorate gas exchange by an altered distribution of VA/Q essentially to lung units with a higher than normal VA/Q." | 1.28 | Cyclooxygenase inhibition aggravates pulmonary hypertension and deteriorates gas exchange in canine pulmonary embolism. ( Delcroix, M; Leeman, M; Lejeune, P; Melot, C; Naeije, R, 1992) |
| "Aspirin (650 mg) was given the night prior to surgery and continued at that dose twice per day." | 1.28 | Aspirin prophylaxis and surveillance of pulmonary embolism and deep vein thrombosis in total hip arthroplasty. ( Jones, K; Lachiewicz, PF; McCardel, BR, 1990) |
| "Pre-treatment with aspirin (5 mg/kg), which inhibits the platelet-release reaction, also prevented the tachypnoeic response to both emboli and antiserum, although it did not prevent the fall in platelet count which following injection of antiserum." | 1.28 | The role of platelets in the reflex tachypnoeic response to miliary pulmonary embolism in anaesthetized rabbits. ( Armstrong, DJ; Miller, SA, 1990) |
| "Picotamide did not inhibit the formation of TxB2 in serum at any of the doses tested (100 to 750 mg/kg i." | 1.28 | Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. ( Alberti, P; Corona, C; Gresele, P; Nenci, GG, 1990) |
| "Pretreatment with methysergide 3 mg/kg also significantly (p less than 0." | 1.27 | The effects of aspirin and methysergide on responses to clot-induced pulmonary embolism. ( Cragg, DB; Forrest, JB; Todd, MH, 1983) |
| "The aspirin-treated dogs had greater resolution of pulmonary arterial proliferative disease, and prednisolone-treated dogs had the lesser resolution." | 1.27 | Pulmonary thromboembolism during therapy of dirofilariasis with thiacetarsamide: modification with aspirin or prednisolone. ( Keith, JC; Rawlings, CA; Schaub, RG, 1983) |
| " A prevention of thromboembolic disease by individual dosage of heparin must be considered in patients at high risk for thromboembolic disease." | 1.27 | [Mortality and morbidity of thromboembolism in drug prevention--5-year analysis]. ( Hopp, A; Hopp, H; Knispel, J, 1988) |
| "Aspirin was administered in the recovery room and continued 600 mg twice a day until discharge." | 1.27 | Activity, air boots, and aspirin as thromboembolism prophylaxis in knee arthroplasty. A multiple regimen approach. ( Clayton, ML; Thompson, TR, 1987) |
| "For treatment of pulmonary thromboembolism, continuous conventional-dose heparin therapy is the approach of choice." | 1.26 | Pulmonary thromboembolism. 2. New trends in prophylaxis and therapy. ( Giudice, JC; Kaufman, J; Komansky, HJ, 1980) |
| "In anesthetized dogs soft tissue trauma resulting in hypovolemia was associated with pulmonary trapping of 51Cr tagged platelets." | 1.25 | Development and treatment of post-traumatic pulmonary platelet trapping. ( Peer, RM; Schwartz, SI, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 101 (29.02) | 18.7374 |
| 1990's | 39 (11.21) | 18.2507 |
| 2000's | 88 (25.29) | 29.6817 |
| 2010's | 82 (23.56) | 24.3611 |
| 2020's | 38 (10.92) | 2.80 |
| Authors | Studies |
|---|---|
| Misra, A | 1 |
| Anil Kumar, KS | 1 |
| Jain, M | 1 |
| Bajaj, K | 1 |
| Shandilya, S | 1 |
| Srivastava, S | 1 |
| Shukla, P | 1 |
| Barthwal, MK | 1 |
| Dikshit, M | 1 |
| Dikshit, DK | 1 |
| Cai, JY | 1 |
| Cui, CM | 1 |
| Min, JK | 1 |
| Cao, YQ | 1 |
| Zhang, LY | 1 |
| Tafazoli, A | 1 |
| Anil Kumar, S | 1 |
| Othman, M | 1 |
| Shohat, N | 1 |
| Goel, R | 2 |
| Ludwick, L | 1 |
| Parvizi, J | 10 |
| Metcalf, KB | 1 |
| Du, JY | 1 |
| Ochenjele, G | 1 |
| Perrotta, C | 2 |
| Chahla, J | 2 |
| Badariotti, G | 2 |
| Ramos, J | 2 |
| Sidhu, VS | 1 |
| Kelly, TL | 1 |
| Pratt, N | 1 |
| Graves, SE | 1 |
| Buchbinder, R | 1 |
| Adie, S | 1 |
| Cashman, K | 1 |
| Ackerman, I | 1 |
| Bastiras, D | 1 |
| Brighton, R | 1 |
| Burns, AWR | 1 |
| Chong, BH | 1 |
| Clavisi, O | 1 |
| Cripps, M | 1 |
| Dekkers, M | 1 |
| de Steiger, R | 1 |
| Dixon, M | 1 |
| Ellis, A | 1 |
| Griffith, EC | 1 |
| Hale, D | 1 |
| Hansen, A | 1 |
| Harris, A | 2 |
| Hau, R | 1 |
| Horsley, M | 1 |
| James, D | 1 |
| Khorshid, O | 1 |
| Kuo, L | 1 |
| Lewis, P | 1 |
| Lieu, D | 1 |
| Lorimer, M | 1 |
| MacDessi, S | 1 |
| McCombe, P | 1 |
| McDougall, C | 1 |
| Mulford, J | 1 |
| Naylor, JM | 1 |
| Page, RS | 1 |
| Radovanovic, J | 1 |
| Solomon, M | 1 |
| Sorial, R | 1 |
| Summersell, P | 1 |
| Tran, P | 1 |
| Walter, WL | 1 |
| Webb, S | 1 |
| Wilson, C | 1 |
| Wysocki, D | 1 |
| Harris, IA | 1 |
| Gris, JC | 1 |
| Bourguignon, C | 1 |
| Bouvier, S | 1 |
| Nouvellon, É | 1 |
| Laurent, J | 1 |
| Perez-Martin, A | 1 |
| Mousty, È | 1 |
| Nikolaeva, MG | 1 |
| Khizroeva, J | 1 |
| Bitsadze, V | 1 |
| Makatsariya, A | 1 |
| Kindell, DG | 1 |
| Marulanda, K | 1 |
| Caruso, DM | 1 |
| Duchesneau, E | 1 |
| Agala, C | 1 |
| Farber, M | 1 |
| Marston, WA | 1 |
| McGinigle, KL | 1 |
| Engler, ID | 3 |
| Maximiliano, CL | 1 |
| Jaime, GC | 1 |
| Erika, MH | 1 |
| O'Toole, RV | 2 |
| Stein, DM | 2 |
| O'Hara, NN | 2 |
| Frey, KP | 1 |
| Taylor, TJ | 1 |
| Scharfstein, DO | 1 |
| Carlini, AR | 1 |
| Sudini, K | 1 |
| Degani, Y | 1 |
| Slobogean, GP | 1 |
| Haut, ER | 1 |
| Obremskey, W | 1 |
| Firoozabadi, R | 1 |
| Bosse, MJ | 1 |
| Goldhaber, SZ | 3 |
| Marvel, D | 1 |
| Castillo, RC | 1 |
| Costa, M | 1 |
| Agarwal, AR | 1 |
| Das, A | 1 |
| Campbell, JC | 1 |
| Golladay, GJ | 1 |
| Thakkar, SC | 1 |
| Heckmann, ND | 1 |
| Piple, AS | 1 |
| Wang, JC | 1 |
| Richardson, MK | 1 |
| Mayfield, CK | 1 |
| Oakes, DA | 1 |
| Christ, AB | 1 |
| Lieberman, JR | 4 |
| Sourmelis, S | 1 |
| Zagoreos, N | 1 |
| Wu, XD | 1 |
| Min, J | 1 |
| Yoshino, T | 1 |
| Yamada, Y | 1 |
| Tamura, Y | 1 |
| Ahuja, T | 1 |
| Green, D | 1 |
| van Twist, DJL | 1 |
| Luu, IHY | 1 |
| Ten Cate, H | 1 |
| Poacher, AT | 1 |
| Hoskins, HC | 1 |
| Protty, MB | 1 |
| Pettit, R | 1 |
| Johansen, A | 1 |
| Tsai, SW | 1 |
| Chang, WL | 1 |
| Pai, FY | 1 |
| Chou, TA | 1 |
| Chen, CF | 1 |
| Wu, PK | 1 |
| Chen, WM | 1 |
| Meng, J | 1 |
| Liu, W | 1 |
| Xiao, Y | 2 |
| Tang, H | 1 |
| Wu, Y | 2 |
| Gao, S | 1 |
| Santos, BC | 1 |
| Flumignan, RL | 1 |
| Civile, VT | 1 |
| Atallah, ÁN | 1 |
| Nakano, LC | 1 |
| Liu, HZ | 1 |
| Liang, J | 1 |
| Hu, AX | 1 |
| Lewis, S | 1 |
| Glen, J | 1 |
| Dawoud, D | 1 |
| Dias, S | 1 |
| Cobb, J | 1 |
| Griffin, X | 1 |
| Reed, M | 1 |
| Sharpin, C | 1 |
| Stansby, G | 1 |
| Barry, P | 1 |
| Seagrave, KG | 1 |
| Fletcher, JP | 1 |
| Hitos, K | 1 |
| Azboy, I | 2 |
| Groff, H | 2 |
| Goswami, K | 1 |
| Vahedian, M | 1 |
| Murphy, RF | 1 |
| Williams, D | 1 |
| Hogue, GD | 1 |
| Spence, DD | 1 |
| Epps, H | 1 |
| Chambers, HG | 1 |
| Shore, BJ | 1 |
| Millar, JS | 1 |
| Lawes, CM | 1 |
| Farrington, B | 1 |
| Andrew, P | 1 |
| Misur, P | 1 |
| Merriman, E | 1 |
| Walker, M | 1 |
| Santana, DC | 1 |
| Emara, AK | 1 |
| Orr, MN | 1 |
| Klika, AK | 2 |
| Higuera, CA | 2 |
| Krebs, VE | 1 |
| Molloy, RM | 1 |
| Piuzzi, NS | 2 |
| Haque, S | 1 |
| Jawed, A | 1 |
| Akhter, N | 1 |
| Dar, SA | 1 |
| Khan, F | 1 |
| Mandal, RK | 1 |
| Areeshi, MY | 1 |
| Lohani, M | 1 |
| Wahid, M | 1 |
| Tang, A | 1 |
| Zak, S | 1 |
| Lygrisse, K | 1 |
| Slover, J | 1 |
| Meftah, M | 1 |
| Lajam, C | 1 |
| Schwarzkopf, R | 1 |
| Macaulay, W | 1 |
| Le, G | 1 |
| Yang, C | 1 |
| Zhang, M | 1 |
| Xi, L | 1 |
| Luo, H | 1 |
| Tang, J | 1 |
| Zhao, J | 1 |
| Kirsch, JM | 1 |
| Gutman, M | 1 |
| Patel, M | 1 |
| Rondon, A | 1 |
| Ramsey, ML | 1 |
| Abboud, JA | 2 |
| Williams, GR | 1 |
| Namdari, S | 1 |
| Tefferi, A | 1 |
| Szuber, N | 1 |
| Pardanani, A | 1 |
| Hanson, CA | 1 |
| Vannucchi, AM | 1 |
| Barbui, T | 1 |
| Gangat, N | 1 |
| Haji Aghajani, M | 1 |
| Moradi, O | 1 |
| Amini, H | 1 |
| Azhdari Tehrani, H | 1 |
| Pourheidar, E | 1 |
| Rabiei, MM | 1 |
| Sistanizad, M | 1 |
| Zhang, Z | 1 |
| Yang, W | 1 |
| Ying, R | 1 |
| Shi, Y | 1 |
| Jiang, H | 1 |
| Cai, D | 1 |
| Kuang, J | 1 |
| Yang, R | 2 |
| Wang, L | 2 |
| Bala, A | 2 |
| Huddleston, JI | 2 |
| Goodman, SB | 2 |
| Maloney, WJ | 2 |
| Amanatullah, DF | 2 |
| Bartlett, M | 1 |
| Mauck, KF | 1 |
| Bierle, DM | 1 |
| Saadiq, RA | 1 |
| Daniels, PR | 1 |
| Quah, C | 1 |
| Bayley, E | 2 |
| Bhamber, N | 1 |
| Howard, P | 1 |
| Cafri, G | 1 |
| Paxton, EW | 2 |
| Chen, Y | 1 |
| Cheetham, CT | 1 |
| Gould, MK | 1 |
| Sluggett, J | 1 |
| Bini, SA | 2 |
| Khatod, M | 2 |
| Gordon, RJ | 1 |
| Lombard, FW | 1 |
| Jones, CW | 1 |
| Spasojevic, S | 1 |
| Goh, G | 1 |
| Joseph, Z | 1 |
| Wood, DJ | 1 |
| Yates, PJ | 1 |
| Sindhu, KK | 1 |
| Cohen, B | 1 |
| Blood, T | 1 |
| Gil, JA | 1 |
| Owens, B | 1 |
| Fleischman, AN | 1 |
| Tan, T | 1 |
| Sterbis, E | 1 |
| Huang, R | 4 |
| Higuera, C | 1 |
| Rothman, RH | 5 |
| Sobh, AH | 1 |
| Koueiter, DM | 1 |
| Mells, A | 1 |
| Siljander, MP | 1 |
| Karadsheh, MS | 1 |
| Faour, M | 1 |
| Brigati, DP | 1 |
| Mont, MA | 1 |
| Barsoum, WK | 1 |
| Zhou, J | 1 |
| Song, Z | 1 |
| Han, M | 1 |
| Yu, B | 1 |
| Lv, G | 1 |
| Han, N | 1 |
| Liu, Z | 1 |
| Yin, J | 1 |
| Oh, J | 1 |
| Bae, JY | 1 |
| Severino, M | 1 |
| Giacomini, T | 1 |
| Verrina, E | 1 |
| Prato, G | 1 |
| Rossi, A | 1 |
| Wells, PS | 1 |
| Prins, MH | 1 |
| Beyer-Westendorf, J | 1 |
| Lensing, AWA | 1 |
| Haskell, L | 1 |
| Levitan, B | 1 |
| Laliberté, F | 1 |
| Ashton, V | 1 |
| Lejeune, D | 1 |
| Crivera, C | 1 |
| Lefebvre, P | 1 |
| Zhao, Q | 1 |
| Yuan, Z | 1 |
| Schein, J | 1 |
| Prandoni, P | 3 |
| Wang, KL | 1 |
| van Es, N | 1 |
| Cameron, C | 1 |
| Castellucci, LA | 1 |
| Büller, HR | 2 |
| Carrier, M | 1 |
| Peñaloza-Martínez, E | 1 |
| Demelo-Rodríguez, P | 1 |
| Proietti, M | 1 |
| Soria Fernández-Llamazares, G | 1 |
| Llamazares-Mendo, C | 1 |
| Álvarez-Sala Walther, L | 1 |
| Marra, AM | 1 |
| Del Toro-Cervera, J | 1 |
| Alyea, E | 1 |
| Gaston, T | 1 |
| Austin, LS | 1 |
| Wowkanech, C | 1 |
| Cypel, B | 1 |
| Pontes, M | 1 |
| Williams, G | 1 |
| Mihara, M | 1 |
| Tamaki, Y | 1 |
| Nakura, N | 1 |
| Takayanagi, S | 1 |
| Saito, A | 1 |
| Ochiai, S | 1 |
| Hirakawa, K | 1 |
| Cohen, AT | 2 |
| Bauersachs, R | 1 |
| Ghosh, A | 1 |
| Best, AJ | 1 |
| Rudge, SJ | 1 |
| Chatterji, U | 1 |
| Murasko, MJ | 1 |
| Burk, DR | 1 |
| Greenberg, B | 1 |
| Neaton, JD | 1 |
| Anker, SD | 1 |
| Byra, WM | 1 |
| Cleland, JGF | 1 |
| Deng, H | 1 |
| Fu, M | 1 |
| La Police, DA | 1 |
| Lam, CSP | 1 |
| Mehra, MR | 1 |
| Nessel, CC | 1 |
| Spiro, TE | 1 |
| van Veldhuisen, DJ | 1 |
| Vanden Boom, CM | 1 |
| Zannad, F | 1 |
| Reddy, VY | 1 |
| Neuzil, P | 1 |
| de Potter, T | 1 |
| van der Heyden, J | 1 |
| Tromp, SC | 1 |
| Rensing, B | 1 |
| Jiresova, E | 1 |
| Dujka, L | 1 |
| Lekesova, V | 1 |
| Sun, C | 1 |
| Wang, LC | 1 |
| Jiang, HF | 1 |
| Yang, RH | 1 |
| Bagratuni, T | 1 |
| Kastritis, E | 1 |
| Politou, M | 1 |
| Roussou, M | 1 |
| Kostouros, E | 1 |
| Gavriatopoulou, M | 1 |
| Eleutherakis-Papaiakovou, E | 1 |
| Kanelias, N | 1 |
| Terpos, E | 1 |
| Dimopoulos, MA | 1 |
| El-Daly, I | 1 |
| Reidy, J | 1 |
| Culpan, P | 1 |
| Bates, P | 1 |
| Raphael, IJ | 3 |
| Tischler, EH | 1 |
| Hozack, WJ | 2 |
| Wu, J | 1 |
| Zhang, W | 1 |
| Zhi, Y | 1 |
| Jiang, R | 1 |
| Barbar, S | 1 |
| Milan, M | 1 |
| Vedovetto, V | 1 |
| Pesavento, R | 1 |
| Harikrishnan, P | 1 |
| Palaniswamy, C | 1 |
| Aronow, WS | 1 |
| Arnold, WV | 2 |
| Januel, JM | 1 |
| Shai, A | 1 |
| Rennert, HS | 1 |
| Rennert, G | 1 |
| Sagi, S | 1 |
| Leviov, M | 1 |
| Lavie, O | 1 |
| Polkowski, GG | 1 |
| Duncan, ST | 1 |
| Bloemke, AD | 1 |
| Schoenecker, PL | 1 |
| Clohisy, JC | 2 |
| Eroglu, M | 1 |
| Senturk, I | 1 |
| Gunay, E | 1 |
| Lawall, H | 1 |
| Oberacker, R | 1 |
| Zemmrich, C | 1 |
| Bramlage, P | 1 |
| Diehm, C | 1 |
| Schellong, SM | 1 |
| Zhang, JT | 1 |
| Chen, KP | 1 |
| Zhang, S | 1 |
| Kucheryavenko, AF | 1 |
| Spasov, AA | 1 |
| Smirnov, AV | 1 |
| Triscott, J | 1 |
| Mercer, S | 1 |
| Tian, PG | 1 |
| Dobbs, B | 1 |
| Thompson, R | 1 |
| Thachil, J | 1 |
| Kaye, ID | 1 |
| Patel, DN | 1 |
| Strauss, EJ | 1 |
| Alaia, MJ | 1 |
| Garofolo, G | 1 |
| Martinez, A | 1 |
| Jazrawi, LM | 1 |
| Braithwaite, I | 1 |
| Dunbar, L | 1 |
| Eathorne, A | 1 |
| Weatherall, M | 1 |
| Beasley, R | 1 |
| Na, YG | 1 |
| Fang, R | 1 |
| Kim, YH | 1 |
| Cho, KJ | 1 |
| Kim, TK | 1 |
| Nam, D | 1 |
| Nunley, RM | 1 |
| Johnson, SR | 1 |
| Keeney, JA | 1 |
| Barrack, RL | 1 |
| Ogonda, L | 1 |
| Hill, J | 1 |
| Doran, E | 1 |
| Dennison, J | 1 |
| Stevenson, M | 1 |
| Beverland, D | 1 |
| Heller, S | 2 |
| Secrist, E | 1 |
| Shahi, A | 1 |
| Chen, AF | 3 |
| Deirmengian, GK | 1 |
| Smith, EB | 1 |
| Maltenfort, M | 1 |
| Brown, S | 1 |
| Bhamber, NS | 1 |
| Howard, PW | 1 |
| Huang, SW | 1 |
| Kuo, HL | 1 |
| Hsu, MT | 1 |
| Tseng, YJ | 1 |
| Lin, SW | 1 |
| Kuo, SC | 1 |
| Peng, HC | 1 |
| Lien, JC | 1 |
| Huang, TF | 1 |
| An, VV | 1 |
| Phan, K | 1 |
| Levy, YD | 1 |
| Bruce, WJ | 1 |
| Radzak, KN | 1 |
| Wages, JJ | 1 |
| Hall, KE | 1 |
| Nakasone, CK | 1 |
| Raheemullah, A | 1 |
| Laurence, TN | 1 |
| Zhao, YT | 1 |
| Tu, I | 1 |
| Schmidt-Braekling, T | 1 |
| Pearle, AD | 1 |
| Mayman, DJ | 1 |
| Westrich, GH | 1 |
| Waldstein, W | 1 |
| Boettner, F | 1 |
| Cheng, V | 1 |
| Cote, MP | 1 |
| Windecker, S | 1 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| Mehran, R | 1 |
| Valgimigli, M | 1 |
| Vranckx, P | 1 |
| Welsh, RC | 1 |
| Baber, U | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Dangas, GD | 1 |
| Shaw, JA | 1 |
| Feldstein, MJ | 1 |
| Low, SL | 1 |
| Woodward, LA | 1 |
| Kwak, HS | 1 |
| Cho, JH | 1 |
| Kim, JT | 1 |
| Yoo, JJ | 1 |
| Kim, HJ | 1 |
| Gameiro, RS | 1 |
| Rodrigues, A | 1 |
| Gonçalves, FM | 1 |
| Graça, JP | 1 |
| Lundberg, GD | 1 |
| Callaghan, JJ | 1 |
| Warth, LC | 1 |
| Hoballah, JJ | 1 |
| Liu, SS | 1 |
| Wells, CW | 1 |
| Lowe, G | 1 |
| Malinovskiĭ, NN | 1 |
| Gruzdev, AK | 1 |
| Beskaeva, LM | 1 |
| Sal' nikov, DV | 1 |
| Nikerov, KIu | 1 |
| Abramov, AS | 1 |
| Fineshin, IN | 1 |
| Millar, JA | 1 |
| Zhang, H | 1 |
| Wu, WD | 1 |
| Biers, SM | 1 |
| Brewster, SF | 1 |
| Kakkos, SK | 1 |
| Caprini, JA | 1 |
| Geroulakos, G | 1 |
| Nicolaides, AN | 1 |
| Stansby, GP | 1 |
| Reddy, DJ | 1 |
| Johanson, NA | 1 |
| Lachiewicz, PF | 4 |
| Lotke, PA | 7 |
| Pellegrini, V | 1 |
| Stringer, TA | 1 |
| Tornetta, P | 1 |
| Haralson, RH | 1 |
| Watters, WC | 1 |
| Cusick, LA | 1 |
| Beverland, DE | 1 |
| Nicol, M | 1 |
| Sun, Y | 1 |
| Craig, N | 1 |
| Wardlaw, D | 1 |
| Barnes, CL | 1 |
| Hanssen, AD | 1 |
| Clarke, HD | 1 |
| Pellegrini, VD | 2 |
| de Peuter, OR | 1 |
| Kok, WE | 1 |
| Torp-Pedersen, C | 1 |
| Kamphuisen, PW | 1 |
| Cleland, JG | 1 |
| Wetsch, WA | 1 |
| Spöhr, F | 1 |
| Teschendorf, P | 1 |
| Böttiger, BW | 1 |
| Padosch, SA | 1 |
| Donohoe, CL | 1 |
| Sayana, MK | 1 |
| Thakral, R | 1 |
| Niall, DM | 1 |
| Inacio, MC | 1 |
| Widmer, BJ | 1 |
| Bassora, R | 1 |
| Warrender, WJ | 1 |
| Khemasuwan, D | 1 |
| Chae, YK | 1 |
| Gupta, S | 1 |
| Carpio, A | 1 |
| Yun, JH | 1 |
| Neagu, S | 1 |
| Lucca, AB | 1 |
| Valsecchi, ME | 1 |
| Mora, JI | 1 |
| Larocca, A | 1 |
| Cavallo, F | 1 |
| Bringhen, S | 1 |
| Di Raimondo, F | 1 |
| Falanga, A | 1 |
| Evangelista, A | 1 |
| Cavalli, M | 1 |
| Stanevsky, A | 1 |
| Corradini, P | 1 |
| Pezzatti, S | 1 |
| Patriarca, F | 1 |
| Cavo, M | 1 |
| Peccatori, J | 1 |
| Catalano, L | 1 |
| Carella, AM | 1 |
| Cafro, AM | 1 |
| Siniscalchi, A | 1 |
| Crippa, C | 1 |
| Petrucci, MT | 1 |
| Yehuda, DB | 1 |
| Beggiato, E | 1 |
| Di Toritto, TC | 1 |
| Boccadoro, M | 1 |
| Nagler, A | 1 |
| Palumbo, A | 1 |
| Jameson, SS | 2 |
| Charman, SC | 2 |
| Gregg, PJ | 2 |
| Reed, MR | 2 |
| van der Meulen, JH | 2 |
| Griffiths, JT | 1 |
| Matthews, L | 1 |
| Pearce, CJ | 1 |
| Calder, JD | 1 |
| Broder, A | 1 |
| Tobin, JN | 1 |
| Putterman, C | 1 |
| Hamilton, SC | 1 |
| Whang, WW | 1 |
| Anderson, BJ | 1 |
| Bradbury, TL | 1 |
| Erens, GA | 1 |
| Roberson, JR | 1 |
| Delgado, MG | 1 |
| Mauri, G | 1 |
| Vega, J | 1 |
| Becattini, C | 1 |
| Agnelli, G | 1 |
| Schenone, A | 1 |
| Eichinger, S | 1 |
| Bucherini, E | 1 |
| Silingardi, M | 1 |
| Bianchi, M | 1 |
| Moia, M | 1 |
| Ageno, W | 1 |
| Vandelli, MR | 1 |
| Grandone, E | 1 |
| Vulcano, E | 1 |
| Gesell, M | 1 |
| Esposito, A | 1 |
| Ma, Y | 1 |
| Memtsoudis, SG | 1 |
| Gonzalez Della Valle, A | 3 |
| Baker, PN | 1 |
| Deehan, DJ | 1 |
| Delluc, A | 1 |
| Lacut, K | 1 |
| Mottier, D | 1 |
| Kahn, JE | 1 |
| Veyssier-Belot, C | 1 |
| Renier, JL | 1 |
| de Mazancourt, P | 1 |
| Peltier, JY | 1 |
| de Raucourt, E | 1 |
| Sobieszczyk, P | 1 |
| Fishbein, MC | 1 |
| Vilela, VS | 1 |
| de Jesús, NR | 1 |
| Levy, RA | 1 |
| Inbal, A | 1 |
| Brotman, DJ | 1 |
| Jaffer, A | 1 |
| Elalamy, I | 1 |
| Hatmi, M | 1 |
| Sheikh, MA | 1 |
| Topoulos, AP | 1 |
| Deitcher, SR | 1 |
| Malacaria, B | 1 |
| Feloney, CD | 1 |
| Biasiutti, FD | 1 |
| Strebel, JK | 1 |
| Braun, S | 1 |
| Jünger, M | 1 |
| Hankey, GJ | 1 |
| Eikelboom, JW | 1 |
| Breddin, HK | 1 |
| Gresele, P | 4 |
| Momi, S | 3 |
| Mezzasoma, AM | 2 |
| Mantilla, CB | 1 |
| Horlocker, TT | 1 |
| Schroeder, DR | 1 |
| Berry, DJ | 1 |
| Brown, DL | 1 |
| Uckun, FM | 1 |
| Vassilev, A | 1 |
| Bartell, S | 1 |
| Zheng, Y | 1 |
| Mahajan, S | 1 |
| Tibbles, HE | 1 |
| Oates-Whitehead, RM | 2 |
| D'Angelo, A | 2 |
| Mol, B | 2 |
| Morimoto, S | 1 |
| Nemoto, M | 1 |
| Han, A | 1 |
| Katoh, S | 1 |
| Kurata, H | 1 |
| Utsunomiya, K | 1 |
| Tajima, N | 1 |
| Kelly, J | 1 |
| Rudd, A | 1 |
| Lewis, RR | 1 |
| Coshall, C | 1 |
| Moody, A | 1 |
| Hunt, BJ | 1 |
| Geerts, WH | 1 |
| Pineo, GF | 1 |
| Heit, JA | 2 |
| Bergqvist, D | 2 |
| Lassen, MR | 1 |
| Colwell, CW | 2 |
| Ray, JG | 1 |
| Ballabeni, V | 2 |
| Tognolini, M | 2 |
| Chiavarini, M | 1 |
| Impicciatore, M | 2 |
| Bruni, R | 2 |
| Bianchi, A | 1 |
| Barocelli, E | 2 |
| Pitchford, SC | 2 |
| Alberti, PF | 1 |
| Minuz, P | 1 |
| Del Soldato, P | 2 |
| Lee, C | 1 |
| Ferguson, C | 1 |
| McNaughton, H | 1 |
| Barber, PA | 1 |
| Gommans, J | 1 |
| Nowitz, M | 1 |
| Levine, M | 2 |
| Wong, D | 1 |
| Brown, DF | 1 |
| Nadel, ES | 1 |
| Lonner, JH | 3 |
| Sarmiento, A | 3 |
| Goswami, A | 1 |
| Grossman, CM | 1 |
| White, JC | 1 |
| Dunn, PM | 1 |
| Stiefelhagen, P | 1 |
| Berend, KR | 1 |
| Lombardi, AV | 1 |
| Abe, T | 1 |
| Hayashi, M | 1 |
| Sakagami, T | 1 |
| Tsutsui, N | 1 |
| Ito, K | 1 |
| Nakajima, H | 1 |
| Haraguchi, M | 1 |
| Brenner, B | 1 |
| Maillardet, L | 1 |
| Richter, ON | 1 |
| Rath, W | 1 |
| Jeong, GK | 1 |
| Gruson, KI | 1 |
| Egol, KA | 1 |
| Aharonoff, GB | 1 |
| Karp, AH | 1 |
| Zuckerman, JD | 2 |
| Koval, KJ | 1 |
| Muntz, JE | 1 |
| O'Connor, PJ | 1 |
| Yin, H | 1 |
| Vogenberg, FR | 1 |
| Bertoni, S | 1 |
| Glynn, RJ | 1 |
| Ridker, PM | 1 |
| Zee, RY | 1 |
| Buring, JE | 1 |
| Beksaç, B | 1 |
| Anderson, J | 1 |
| Sharrock, NE | 3 |
| Sculco, TP | 1 |
| Salvato, EA | 1 |
| Dorr, LD | 2 |
| Gendelman, V | 1 |
| Maheshwari, AV | 1 |
| Boutary, M | 1 |
| Wan, Z | 1 |
| Long, WT | 1 |
| Go, G | 2 |
| Lyman, S | 1 |
| Salvati, EA | 4 |
| Tymvios, C | 1 |
| Jones, S | 1 |
| Moore, C | 1 |
| Page, CP | 2 |
| Emerson, M | 2 |
| Tian, H | 1 |
| Song, F | 1 |
| Zhang, K | 1 |
| Liu, Y | 1 |
| Bekemeier, H | 1 |
| Leuschner, G | 1 |
| Schmollack, W | 1 |
| Borow, M | 2 |
| Goldson, H | 1 |
| Westermann, K | 1 |
| Trentz, O | 1 |
| Pretschner, P | 1 |
| Mellmann, J | 1 |
| Kugelmeier, J | 1 |
| Egloff, L | 1 |
| Kakkar, VV | 4 |
| Zielinsky, A | 1 |
| Hirsh, J | 7 |
| Geyer, U | 1 |
| Russell, JC | 1 |
| Goldson, HJ | 1 |
| Fitzpatrick, JW | 1 |
| Giudice, JC | 2 |
| Papa, L | 1 |
| Freed, N | 1 |
| Szabó, R | 2 |
| Karády, I | 1 |
| Hörcher, A | 1 |
| Gyetvai, A | 2 |
| Kohán, M | 2 |
| Szöllösi, K | 1 |
| Todd, MH | 4 |
| Forrest, JB | 4 |
| Cragg, DB | 3 |
| Alho, A | 1 |
| Stangeland, L | 1 |
| Røttingen, J | 1 |
| Wiig, JN | 1 |
| Keith, JC | 4 |
| Rawlings, CA | 3 |
| Losonsky, JM | 2 |
| McCall, JM | 1 |
| Mantero, O | 1 |
| Colli, S | 1 |
| Maderna, P | 1 |
| Lo Cicero, S | 1 |
| Bertoli, L | 1 |
| Tremoli, E | 1 |
| Ali, M | 1 |
| McDonald, JW | 1 |
| Klotz, TA | 1 |
| Cohn, LS | 1 |
| Zipser, RD | 1 |
| Salzman, EW | 4 |
| Davies, GC | 1 |
| Lewis, RE | 1 |
| McCall, JW | 1 |
| Schaub, RG | 1 |
| McKenna, R | 1 |
| Galante, J | 1 |
| Bachmann, F | 1 |
| Wallace, DL | 1 |
| Kaushal, PS | 1 |
| Meredith, P | 1 |
| Verstraete, M | 2 |
| Shier, MR | 1 |
| Wilson, RF | 1 |
| Covey, TH | 1 |
| Baue, AE | 1 |
| Zekert, F | 5 |
| Schemper, M | 2 |
| Neumann, K | 1 |
| Stulberg, BN | 1 |
| Ranawat, CS | 2 |
| Schneider, R | 1 |
| Guyer, RD | 1 |
| Booth, RE | 1 |
| DeLee, JC | 1 |
| Rockwood, CA | 1 |
| Komansky, HJ | 1 |
| Kaufman, J | 1 |
| Genton, E | 3 |
| Nozdrachev, IuI | 1 |
| Monreal, M | 1 |
| Lafoz, E | 1 |
| Roca, J | 1 |
| Granero, X | 1 |
| Soler, J | 1 |
| Salazar, X | 1 |
| Olazabal, A | 1 |
| Feldman, DS | 1 |
| Walters, I | 1 |
| Sakales, SR | 1 |
| Ueno, Y | 2 |
| Kawashima, A | 1 |
| Koike, H | 2 |
| Nishio, S | 2 |
| Warwick, DJ | 1 |
| Seagroatt, V | 1 |
| Bulstrode, C | 1 |
| Murray, DW | 1 |
| Lee, HC | 1 |
| Laya, MB | 1 |
| Shibuya, Y | 1 |
| Tanaka, H | 1 |
| Abe, S | 1 |
| Palevsky, H | 1 |
| Keenan, AM | 1 |
| Meranze, S | 1 |
| Steinberg, ME | 1 |
| Ecker, ML | 1 |
| Kelley, MA | 1 |
| Laupacis, A | 1 |
| Rorabeck, C | 1 |
| Bourne, R | 1 |
| Tugwell, P | 1 |
| Bullas, R | 1 |
| Rankin, R | 1 |
| Vellet, AD | 1 |
| Feeny, D | 1 |
| Wong, C | 1 |
| Collins, R | 1 |
| MacMahon, S | 1 |
| Flather, M | 1 |
| Baigent, C | 1 |
| Remvig, L | 1 |
| Mortensen, S | 1 |
| Appleby, P | 1 |
| Godwin, J | 1 |
| Yusuf, S | 1 |
| Peto, R | 1 |
| Williams-Russo, P | 1 |
| Haas, SB | 2 |
| Insall, J | 1 |
| Windsor, RE | 2 |
| Laskin, RS | 1 |
| Ganz, SB | 1 |
| Klein, JA | 1 |
| Holleman, JB | 1 |
| Kelley, S | 1 |
| Annoh, S | 1 |
| Horie, S | 1 |
| Yamada, M | 1 |
| Satoh, M | 1 |
| Noritake, S | 1 |
| Hiraishi, S | 1 |
| Kizaki, K | 1 |
| Kurusu, O | 1 |
| Nakahara, T | 1 |
| Ishii, H | 1 |
| Kazama, M | 1 |
| Prentice, CR | 1 |
| McNeely, W | 1 |
| Goa, KL | 1 |
| Krasuski, M | 1 |
| Jagodziński, K | 1 |
| Kiwerski, JE | 1 |
| Krzyzosiak, L | 1 |
| Goswami, AD | 1 |
| Beuhler, KO | 1 |
| D'Lima, DD | 1 |
| Otis, SM | 1 |
| Walker, RH | 1 |
| Kang, WS | 1 |
| Lim, IH | 1 |
| Yuk, DY | 1 |
| Chung, KH | 1 |
| Park, JB | 1 |
| Yoo, HS | 1 |
| Yun, YP | 1 |
| Morimoto, Y | 1 |
| Sugimoto, T | 1 |
| Okada, M | 1 |
| Mukai, T | 1 |
| Sors, H | 1 |
| Meyer, G | 1 |
| Paul, W | 1 |
| Leone, M | 1 |
| Freedman, KB | 1 |
| Brookenthal, KR | 1 |
| Fitzgerald, RH | 1 |
| Williams, S | 1 |
| Henley, E | 1 |
| Sheu, JR | 3 |
| Hung, WC | 1 |
| Wu, CH | 1 |
| Lee, YM | 3 |
| Yen, MH | 3 |
| Cohen, A | 2 |
| Quinlan, D | 2 |
| Cimminiello, C | 1 |
| Tauzeeh, SM | 1 |
| Mahé, I | 1 |
| Bergmann, JF | 1 |
| Mahé, E | 1 |
| Caulin, C | 1 |
| Smulders, Y | 1 |
| Kalsi, GS | 1 |
| Parker, M | 1 |
| Thomas, DP | 2 |
| Poullis, M | 1 |
| Ginsberg, JS | 1 |
| Greer, I | 1 |
| Waitkevicz, HJ | 1 |
| Axelrod, D | 1 |
| Hsiao, G | 2 |
| Sandercock, P | 1 |
| Dennis, M | 1 |
| Proctor, MC | 1 |
| Greenfield, LJ | 1 |
| Grace, DL | 1 |
| Mesko, JW | 1 |
| Brand, RA | 1 |
| Iorio, R | 1 |
| Gradisar, I | 1 |
| Heekin, R | 1 |
| Leighton, R | 1 |
| Thornberry, R | 1 |
| Moyad, MA | 1 |
| Tufano, A | 1 |
| Cerbone, AM | 1 |
| Di Minno, G | 1 |
| McCahill, JP | 1 |
| Carrington, RW | 1 |
| Skinner, JA | 1 |
| Loo, J | 1 |
| Medici, TC | 1 |
| Peer, RM | 2 |
| Schwartz, SI | 2 |
| Wiggins, CE | 1 |
| Harris, WH | 4 |
| Athanasoulis, CA | 1 |
| Waltman, AC | 2 |
| DeSanctis, RW | 3 |
| Sasahara, AA | 1 |
| Sharma, GV | 1 |
| Parisi, AF | 1 |
| Uhl, JF | 1 |
| Huguier, M | 1 |
| Kohn, P | 2 |
| Müller, M | 1 |
| Cragg, DJ | 1 |
| Hull, R | 1 |
| Delmore, TJ | 1 |
| Gent, M | 3 |
| Armstrong, P | 1 |
| Lofthouse, R | 1 |
| MacMillan, A | 1 |
| Blackstone, I | 1 |
| Reed-Davis, R | 1 |
| Detwiler, RC | 1 |
| Schulman, JD | 1 |
| Agarwal, B | 1 |
| Mudd, SH | 1 |
| Shulman, NR | 1 |
| Schöndorf, TH | 3 |
| Breddin, K | 1 |
| Scharrer, I | 1 |
| Vormittag, E | 1 |
| Wierzbicki, R | 1 |
| Massalski, WK | 1 |
| Brady, LP | 1 |
| Weber, U | 1 |
| Lasch, HG | 1 |
| Buttermann, G | 1 |
| Theisinger, W | 1 |
| Weidenbach, A | 1 |
| Hartung, R | 1 |
| Welzel, D | 1 |
| Pabst, HW | 1 |
| Lachiewicz, P | 1 |
| Jennings, JJ | 1 |
| Lavrinovitsch, TS | 1 |
| Petuchova, LI | 1 |
| Slutskii, LI | 1 |
| Hey, D | 2 |
| Harker, LA | 1 |
| Tomikawa, M | 1 |
| Lindquist, O | 1 |
| Saldeen, T | 1 |
| Sandler, H | 1 |
| Mohr, DN | 1 |
| Silverstein, MD | 1 |
| Ilstrup, DM | 1 |
| Morrey, BF | 1 |
| Tribus, CB | 1 |
| Insall, JN | 1 |
| Becker, MW | 1 |
| Delcroix, M | 1 |
| Melot, C | 1 |
| Lejeune, P | 1 |
| Leeman, M | 1 |
| Naeije, R | 1 |
| Mohr, VD | 1 |
| Lenz, J | 1 |
| Schneider, J | 1 |
| Genyk, SN | 1 |
| Orishchak, DT | 1 |
| Trubuhovich, RV | 1 |
| Kawamura, Y | 1 |
| Hasebe, N | 1 |
| Matsuhashi, H | 1 |
| Ernst, E | 1 |
| McCardel, BR | 1 |
| Jones, K | 1 |
| Orthner, E | 1 |
| Hertz, H | 1 |
| Kwasny, O | 1 |
| Maier, R | 1 |
| Höfer, R | 1 |
| Bergmann, H | 1 |
| Havlick, E | 1 |
| Wohlzogen, FX | 1 |
| Armstrong, DJ | 1 |
| Miller, SA | 1 |
| Corona, C | 1 |
| Alberti, P | 1 |
| Nenci, GG | 1 |
| Hull, RD | 2 |
| Raskob, GE | 2 |
| Clagett, GP | 1 |
| Reisch, JS | 1 |
| Coffman, JD | 1 |
| Powers, PJ | 1 |
| Jay, RM | 1 |
| Julian, DH | 1 |
| Turpie, AG | 1 |
| Tomai, F | 1 |
| Gioffrè, PA | 1 |
| Pieri, S | 1 |
| Palange, MA | 1 |
| Valci, F | 1 |
| Varga, G | 1 |
| Lengyel, A | 1 |
| Zanasi, R | 1 |
| Fioretta, G | 1 |
| Ciocia, G | 1 |
| Bergonzi, M | 1 |
| Josefsson, G | 1 |
| Dahlqvist, A | 1 |
| Bodfors, B | 1 |
| Hopp, H | 1 |
| Hopp, A | 1 |
| Knispel, J | 1 |
| Alfaro, MJ | 1 |
| Páramo, JA | 2 |
| Rocha, E | 2 |
| Isada, N | 1 |
| Kessler, C | 1 |
| Larsen, J | 1 |
| Weingold, A | 1 |
| Clayton, ML | 1 |
| Thompson, TR | 1 |
| Alfaro, M | 1 |
| de Pablos, J | 1 |
| Cañadell, J | 1 |
| Weiner, CP | 1 |
| Vane, JR | 1 |
| Kingdon, HS | 1 |
| Aglietti, P | 1 |
| Mendes, DG | 1 |
| Wilson, PD | 1 |
| Nakano, J | 2 |
| Hampton, J | 1 |
| Ardelt, W | 1 |
| Dittrich, A | 1 |
| Bolze, H | 1 |
| Athanasoulis, C | 1 |
| Baum, S | 1 |
| Lyon, LJ | 1 |
| Nevins, MA | 1 |
| Mandel, SR | 1 |
| Johnson, G | 1 |
| Neef, H | 1 |
| Preusser, KP | 1 |
| Edwards, IR | 1 |
| Walker, AE | 1 |
| Koss, MC | 1 |
| Gallus, AS | 1 |
| Encke, A | 1 |
| Currier, RD | 1 |
| Haerer, AF | 1 |
| Heinrich, D | 1 |
| Burkhardt, H | 1 |
| Skillman, JJ | 1 |
| Naess, K | 1 |
| Sherry, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Different Doses of Pregabalin as a Multimodal Analgesic Agent in Postoperative Pain Control After Total Knee Arthroplasty - A Randomized Controlled Trial[NCT05447364] | Phase 4 | 82 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | ||
| Pneumatic Compression Versus Anti-thromboembolic Exercises: Effects on Edema of the Lower Limbs and the Outcomes of Patients Undergoing Total Hip Arthroplasty: Randomized Controlled Clinical Trial[NCT05312060] | 48 participants (Anticipated) | Interventional | 2022-04-11 | Enrolling by invitation | |||
| Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy[NCT04352439] | Phase 4 | 19 participants (Actual) | Interventional | 2020-08-08 | Completed | ||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Diseas[NCT01877915] | Phase 3 | 5,081 participants (Actual) | Interventional | 2013-09-10 | Completed | ||
| Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients[NCT03571789] | 25 participants (Actual) | Interventional | 2017-09-12 | Active, not recruiting | |||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices[NCT02345642] | 20 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.[NCT00222677] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2004-05-31 | Active, not recruiting | ||
| Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients[NCT04445623] | Phase 3 | 128 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention[NCT00187408] | Phase 4 | 700 participants | Interventional | 2002-08-31 | Completed | ||
| Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698[NCT00769873] | Phase 2 | 35 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.) | ||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| Multiple Algorithms System Of All Scores in Embolism - MOSE[NCT02911012] | 15,208 participants (Anticipated) | Observational | 2016-10-31 | Recruiting | |||
| Toronto Thromboprophylaxis Patient Safety Initiative (TOPPS): A Cluster Randomized Trial[NCT01869075] | 1,895 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Multi-Screen Electronic Alert for Venous Thromboembolism Prevention[NCT00550082] | 880 participants (Actual) | Observational | 2007-07-31 | Completed | |||
| The Protective Effect of Transcutaneous Electrical Acupoint Stimulation (TEAS) on Aged Patients Undergoing Lower Extremity Arthroplasty: A Single-Center, Double-Blinded, Randomised Controlled Trial[NCT02979028] | 300 participants (Anticipated) | Interventional | 2017-05-01 | Not yet recruiting | |||
| Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928] | 70 participants (Actual) | Observational | 2012-12-03 | Completed | |||
| The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Pain Treatment After Total Knee Replacement - Continuous Epidural Versus Intravenous Patient Controlled Analgesia With Morphine[NCT00270322] | Phase 4 | 80 participants | Interventional | 2006-01-31 | Terminated (stopped due to We believe regional anesth better for TKR,90% patients got epidural. Last year we started spinal morphine one shot, and found it very promissing.) | ||
| Influence of Tourniquet Use and Surgery Duration on the Incidence of Deep Vein Thrombosis in Total Knee Arthroplasty[NCT01559532] | 78 participants (Actual) | Observational | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04352439)
Timeframe: Up to six months
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 4 |
Adverse events will only include those that are determined to be related to the study drug. (NCT04352439)
Timeframe: Up to six months
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 0 |
Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 24.84 |
| Placebo | 24.57 |
Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.44 |
| Placebo | 14.27 |
Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 1.52 |
| Placebo | 1.16 |
Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 9.46 |
| Placebo | 9.96 |
Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 23.32 |
| Placebo | 23.46 |
Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 2.04 |
| Placebo | 1.21 |
Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.30 |
| Placebo | 14.04 |
Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 17.24 |
| Placebo | 17.45 |
Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) | |
|---|---|---|
| Fatal Bleeding | Critical Space Bleeding with Permanent Disability | |
| Placebo | 0.22 | 0.48 |
| Rivaroxaban | 0.22 | 0.32 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
Ultrasound of the venous system just below the saphenofemoral junction to assess the venous velocity will be taken before and after application the VenaFlow and the ActiveCare+S.F.T pneumatic compression devices. Change from Baseline in Peak Venous Velocity 30 minutes after Device is applied is recorded. (NCT02345642)
Timeframe: Change from Baseline in Peak Venous Velocity 30 minutes after Device is Applied
| Intervention | cm/s (Mean) | |||
|---|---|---|---|---|
| Delta PVV from before to after Venaflow (Standing) | Delta PVV from before to after Venaflow (Supine) | delta PVV from before to after Activeca (Standing) | delta PVV from before to after Activecare (supine) | |
| 10 Healthy Patients Without THA | 127.9 | 87.1 | 32.6 | 40.5 |
| 10 Patients With THA on Post-Op Day 2 | 155.7 | 86.8 | 41.9 | 37.8 |
"Rates of appropriate VTE prophylaxis were determined as the number of patients who received VTE prophylaxis as a proportion of the number of patient at risk.~Rates reported are for the active phases (phase 1 and phase 2) and compare intervention to control.~Appropriate VTE prophylaxis was defined as:~in Hip Fracture Surgery - evidence-based VTE prophylaxis ordered within 24 of admission, restarted within 24 hours after surgery and continued for at least 10 days post-discharge in Major General Surgery - evidence-based VTE prophylaxis ordered within 24 hours post-surgery and continued for the duration of hospital stay in Acute Medical Illness - evidence-based VTE prophylaxis ordered within 24 hours of admission and continued for the duration of hospital stay.~Evidence-based VTE prophylaxis was determined to be according to the American College of Chest Physicians (ACCP) guidelines. The 9th version was the most current version at the time of the study." (NCT01869075)
Timeframe: End of study (end of phase 2) - measured over duration of hospital stay.
| Intervention | percentage of patients (Number) |
|---|---|
| AMI - Knowledge Translation Toolkit | 64 |
| AMI - Usual Care | 62 |
| MGS - Knowledge Translation Toolkit | 67 |
| MGS - Usual Care | 54 |
| HFS - Knowledge Translation Toolkit | 85 |
| HFS - Usual Care | 76 |
Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury
| Intervention | participants (Number) |
|---|---|
| Fondaparinux Sodium | 0 |
Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3
| Intervention | Participants (Number) | |
|---|---|---|
| Trough values outside normative range | Peak values outside normative range | |
| Fondaparinux Sodium | 0 | 0 |
Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury
| Intervention | participants (Number) | ||
|---|---|---|---|
| DVT | DVT after fondaparinux | PE | |
| Fondaparinux Sodium | 2 | 1 | 0 |
| No Fondaparinux | 2 | NA | 0 |
79 reviews available for aspirin and Embolism, Pulmonary
| Article | Year |
|---|---|
Comparison between use of direct oral anticoagulants and aspirin for risk of thromboembolism complications in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Factor Xa Inhibitors | 2021 |
Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications.
Topics: Abciximab; Acute Disease; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; COVID-19; COVID-19 | 2022 |
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Topics: Adult; Anticoagulants; Arthroscopy; Aspirin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Huma | 2022 |
The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Heparin; Heparin, Low-Molecular-Weight; Hu | 2023 |
Prophylactic anticoagulants for non-hospitalised people with COVID-19.
Topics: Anticoagulants; Aspirin; COVID-19; Humans; Platelet Aggregation Inhibitors; Pulmonary Embolism; Veno | 2023 |
The efficacy and safety of aspirin in preventing venous thrombosis in major orthopedic surgery: An updated meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; P | 2023 |
Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Bayes Theorem; Cost-Benefit Analysis; Elect | 2019 |
Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence.
Topics: Anticoagulants; Aspirin; Evidence-Based Medicine; Hemorrhage; Humans; Lower Extremity; Orthopedic Pr | 2019 |
Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review.
Topics: Anticoagulants; Arthroplasty; Aspirin; Humans; Joints; Pulmonary Embolism; Venous Thromboembolism | 2020 |
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Topics: Adult; Anticoagulants; Arthroscopy; Aspirin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecula | 2020 |
An Update on Venous Thromboembolism Rates and Prophylaxis in Hip and Knee Arthroplasty in 2020.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemor | 2020 |
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Topics: Adolescent; Adult; Aspirin; Calreticulin; Disease-Free Survival; Erythrocyte Transfusion; Female; Fo | 2021 |
Updates in venous thromboembolism management: evidence published in 2016.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Factor Xa | 2017 |
Perioperative Venous Thromboembolism: A Review.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductas | 2017 |
Upper Extremity Deep Venous Thrombosis Prophylaxis After Elective Upper Extremity Surgery.
Topics: Aged; Aspirin; Cardiology; Comorbidity; Compression Bandages; Elective Surgical Procedures; Humans; | 2018 |
Extended treatment of venous thromboembolism: a systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Humans; Network Meta-Analysis; Platelet Aggregation Inhibitors; Pulmonary E | 2019 |
Update on extended treatment for venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; | 2018 |
Rivaroxaban and the EINSTEIN clinical trial programme.
Topics: Adult; Aspirin; Child; Clinical Trials as Topic; Humans; Precision Medicine; Pulmonary Embolism; Riv | 2019 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparin | 2013 |
Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inh | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; | 2014 |
Update on pharmacologic therapy for pulmonary embolism.
Topics: Animals; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Hydrox | 2014 |
Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Hemorr | 2015 |
Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease.
Topics: Aged, 80 and over; Anticoagulants; Aspirin; Enoxaparin; Erythrocyte Transfusion; Female; Hematoma; H | 2015 |
Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemor | 2016 |
Pulmonary Embolism Rates Following Total Hip Arthroplasty With Prophylactic Anticoagulation: Some Pulmonary Emboli Cannot Be Avoided.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Aspirin; Factor Xa Inhibitors; Health | 2017 |
Rational thromboprophylaxis in medical inpatients: not quite there yet.
Topics: Anticoagulants; Aspirin; Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Evidence-Based | 2008 |
Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thrombo-embolism in high-risk patients.
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Intermittent Pneumatic Compression D | 2009 |
Systolic heart failure: a prothrombotic state.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2009 |
[Thrombolysis during cardio-pulmonary resuscitation].
Topics: Aspirin; Cardiopulmonary Resuscitation; Contraindications; Death, Sudden, Cardiac; Fibrinolytic Agen | 2010 |
Aspirin for lower limb arthroplasty thromboprophylaxis: review of international guidelines.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fondaparin | 2011 |
[Aspirin for secondary prevention of venous thromboembolism. WARFASA: far from being conclusive].
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Pulmonary Embolism; Randomized Controlled Trials as Top | 2013 |
Prevention of thrombosis during pregnancy.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulation Tests; B | 2002 |
[What is the place of aspirin in venous thrombosis prophylaxis?].
Topics: Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Practice Guidelines as Topic; Pulmona | 2002 |
[Anticoagulation and antiaggregation during pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Abruptio Placentae; Administration, Oral; Adult; | 2003 |
[Traveler's thrombosis].
Topics: Adult; Age Factors; Aged; Aircraft; Anticoagulants; Aspirin; Case-Control Studies; Clinical Trials a | 2003 |
Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery.
Topics: Anticoagulants; Aspirin; Female; Gynecologic Surgical Procedures; Heparin; Humans; Postoperative Com | 2003 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Best evidence topic report. Aspirin in the treatment of acute pulmonary embolism.
Topics: Acute Disease; Aspirin; Emergencies; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitor | 2005 |
Management problems of spontaneous ICH.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitalization; Humans; Magnetic Reso | 2005 |
[Patient with antithrombotic medication. Which do bleedings or preoperative?].
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atherosc | 2006 |
Multimodal venous thromboembolic disease prevention for patients undergoing primary or revision total joint arthroplasty: the role of aspirin.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Dose-Response Relationship | 2006 |
Travel-related thrombosis: is this a problem?
Topics: Aerospace Medicine; Aircraft; Anticoagulants; Aspirin; Chemoprevention; Heparin; Humans; Posture; Pr | 2006 |
[Thromboembolic diseases in pregnancy].
Topics: Algorithms; Anticoagulants; Aspirin; Contraindications; Coumarins; Female; Heparin; Heparin, Low-Mol | 2007 |
WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery.
Topics: Anticoagulants; Aspirin; Female; Gynecologic Surgical Procedures; Heparin; Humans; Postoperative Com | 2007 |
Aspirin prophylaxis for thromboembolic disease after total joint arthroplasty.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Aspirin; Humans; Postoperative C | 2007 |
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
Topics: Anesthesia, Conduction; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, K | 2008 |
[Pulmonary embolism in surgical patients (author's transl)].
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Bed Rest; Dextrans; Female; Heart Failure; Humans; Intes | 1980 |
Prevention of venous thromboembolism.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Dextrans; Dihydroergotamine; Dipyridamo | 1981 |
Prophylaxis of postoperative deep vein thrombosis and pulmonary embolism.
Topics: Adult; Age Factors; Anticoagulants; Aspirin; Clothing; Dextrans; Early Ambulation; Heparin; Hip Join | 1983 |
Eicosanoids and venous thromboembolism.
Topics: Animals; Arachidonic Acids; Aspirin; Dipyridamole; Dogs; Epoprostenol; Hemostasis; Humans; Platelet | 1983 |
[Critical evaluation of the usefulness of drugs inhibiting platelet function in the prevention of postoperative deep venous thrombosis and in ischemic cardiopathy].
Topics: Anticoagulants; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Fibrinolytic Agents; Flurbiprof | 1980 |
Fat embolism syndrome: traumatic coagulopathy with respiratory distress.
Topics: Adrenal Cortex Hormones; Aspirin; Blood Coagulation Disorders; Blood Platelets; Cholesterol; Embolis | 1980 |
Low-dose heparin: an aid to therapy.
Topics: Aspirin; Clinical Trials as Topic; Dihydroergotamine; Double-Blind Method; Electric Stimulation; Hem | 1980 |
[Emergency drug therapy of pulmonary thromboembolism].
Topics: Anticoagulants; Aspirin; Emergencies; Heparin; Humans; Plasminogen Activators; Platelet Aggregation | 1995 |
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Heparin; Humans; Myoc | 1996 |
Triflusal.
Topics: Adult; Angina Pectoris; Animals; Aspirin; Carotid Stenosis; Humans; In Vitro Techniques; Middle Aged | 1998 |
The role of aspirin for thromboembolic disease in total joint arthroplasty.
Topics: Arthroplasty, Replacement, Hip; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Huma | 1999 |
A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Chemoprevention; Confidence Intervals | 2000 |
Use of antithrombotic agents during pregnancy.
Topics: Aspirin; Female; Fetus; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregn | 2001 |
An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2; Cycloox | 2001 |
The use of antithrombotic drugs in older people.
Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo | 2002 |
Current concepts in venous thromboembolism and major lower limb orthopaedic surgery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Aspirin; Heparin, Low-Molecular- | 2002 |
New developments in the detection and prevention of venous thromboembolism.
Topics: Aspirin; Clothing; Dextrans; Electric Stimulation Therapy; Fibrinolytic Agents; Heparin; Hip Joint; | 1979 |
[Prevention of thrombosis and embolism in digestive surgery].
Topics: Anticoagulants; Aspirin; Coumarins; Dextrans; Digestive System Surgical Procedures; Dipyridamole; He | 1979 |
[Pulmonary thromboembolism].
Topics: Aspirin; Dextrans; Drug Evaluation; Fibrinolytic Agents; Heparin; Humans; Postoperative Complication | 1991 |
[Prevention of postoperative venous thrombosis and pulmonary embolism. Consensus conference 8 March 1991 by Assistance Publique-Hopitaux de Paris].
Topics: Anesthesia; Aspirin; Bandages; Dextrans; Female; France; Heparin, Low-Molecular-Weight; Humans; Male | 1991 |
Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis.
Topics: Adult; Aspirin; Clinical Trials as Topic; Clothing; Dextrans; Dihydroergotamine; Drug Combinations; | 1988 |
Deep venous thrombosis and pulmonary emboli: etiology, medical treatment, and prophylaxis.
Topics: Ancrod; Aspirin; Dextrans; Fibrinolytic Agents; Heparin; Humans; Pulmonary Embolism; Risk Factors; T | 1989 |
[The role of colfarit in the prevention of pulmonary embolism the aged].
Topics: Age Factors; Aspirin; Female; Humans; Male; Middle Aged; Pulmonary Embolism | 1988 |
Diagnosis and management of thromboembolic disease during pregnancy.
Topics: Acute Disease; Aspirin; Bacterial Infections; Female; Heparin; Humans; Ovary; Phlebography; Plethysm | 1985 |
The prostaglandins: their significance in clinical practice.
Topics: Abortion, Induced; Anemia, Hemolytic; Animals; Aspirin; Asthma; Chemical Phenomena; Chemistry; Cycli | 1974 |
Trends in the development of antithrombotic agents.
Topics: Adenine Nucleotides; Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Anticoagulants; As | 1971 |
Prevention of thromboembolism after hip fracture.
Topics: Aged; Anticoagulants; Aspirin; Bandages; Coumarins; Dextrans; Exercise Therapy; Femoral Neck Fractur | 1973 |
Prevention and management of venous thrombosis and pulmonary embolism.
Topics: Anticoagulants; Aspirin; Coumarins; Dextrans; Dipyridamole; Female; Heparin; Humans; Male; Methods; | 1973 |
[Urgency and technic of thromboembolism prevention in surgery].
Topics: Anticoagulants; Aspirin; Blood Circulation; Blood Platelets; Heparin; Humans; Postoperative Complica | 1973 |
Deep venous thrombosis. II. Management.
Topics: Anticoagulants; Aspirin; Dextrans; Heparin; Humans; Postoperative Complications; Pulmonary Embolism; | 1973 |
Pathophysiologic roles of prostaglandins and the action of aspirin-like drugs.
Topics: Analgesics; Animals; Aspirin; Cardiovascular System; Cats; Central Nervous System; Diarrhea; Digesti | 1973 |
The diagnosis and prevention of post operative venous thrombosis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Depression, Chemical; Dextrans; Fibr | 1973 |
48 trials available for aspirin and Embolism, Pulmonary
| Article | Year |
|---|---|
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Aust | 2022 |
Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban.
Topics: Acenocoumarol; Anticoagulants; Aspirin; Hemorrhage; Humans; Ischemic Stroke; Pilot Projects; Pulmona | 2023 |
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
Topics: Adult; Anticoagulants; Aspirin; Chemoprevention; Extremities; Fractures, Bone; Hemorrhage; Heparin, | 2023 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Permanent Percutaneous Carotid Artery Filter to Prevent Stroke in Atrial Fibrillation Patients: The CAPTURE Trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Carotid Artery, Common; Clopidogrel; Embolic Pro | 2019 |
Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial.
Topics: Adolescent; Adult; Aged; Arthroscopy; Aspirin; Drug Administration Schedule; Female; Fibrinolytic Ag | 2015 |
Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
A Comparison of Two Dosing Regimens of ASA Following Total Hip and Knee Arthroplasties.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clinical Protocols; | 2017 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty.
Topics: Aged; Anesthesia; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; A | 2003 |
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study.
Topics: 3' Untranslated Regions; Activated Protein C Resistance; Adult; Aspirin; Double-Blind Method; Drug A | 2007 |
[Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthr | 2007 |
Thromboembolism after hip surgery.
Topics: Aspirin; Clinical Trials as Topic; Dextrans; Dihydroergotamine; Dipyridamole; Drug Therapy, Combinat | 1981 |
[The effect of low doses of Colfarit on pulmonary embolism in the elderly].
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Delayed-Action Preparations; F | 1984 |
Prophylaxis of venous thromboembolism by aspirin, warfarin and heparin in patients with hip fracture. A prospective clinical study with cost-benefit analysis.
Topics: Adult; Aspirin; Cost-Benefit Analysis; Female; Heparin; Hip Fractures; Humans; Male; Prospective Stu | 1984 |
Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression.
Topics: Adult; Age Factors; Aged; Aspirin; Blood Coagulation Tests; Clinical Trials as Topic; Drug Administr | 1980 |
Low-dose heparin: an aid to therapy.
Topics: Aspirin; Clinical Trials as Topic; Dihydroergotamine; Double-Blind Method; Electric Stimulation; Hem | 1980 |
Acetylsalicylic acid in combination with dihydroergotamine for preventing thromboembolism.
Topics: Adult; Aged; Aspirin; Dihydroergotamine; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male | 1982 |
Platelet count, antiplatelet therapy and pulmonary embolism--a prospective study in patients with hip surgery.
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage | 1995 |
Antiplatelet therapy to prevent thrombosis after hip fracture.
Topics: Aged; Aspirin; Drug Interactions; Heparin; Hip Fractures; Humans; Platelet Aggregation Inhibitors; P | 1995 |
Thromboembolism after THR: prophylaxis and treatment.
Topics: Adult; Aged; Anesthesia, Epidural; Anesthesia, General; Aspirin; Bandages; Blood Loss, Surgical; Fem | 1995 |
Aspirin and warfarin for thromboembolic disease after total joint arthroplasty.
Topics: Aged; Anticoagulants; Aspirin; Female; Humans; Joint Prosthesis; Male; Platelet Aggregation Inhibito | 1996 |
The frequency of venous thrombosis in cemented and non-cemented hip arthroplasty.
Topics: Aged; Anticoagulants; Aspirin; Female; Hip Prosthesis; Humans; Male; Middle Aged; Ontario; Phlebogra | 1996 |
Randomized trial of epidural versus general anesthesia: outcomes after primary total knee replacement.
Topics: Aged; Anesthesia, Epidural; Anesthesia, General; Aspirin; Female; Humans; Knee Prosthesis; Male; Mid | 1996 |
Place of aspirin in prophylaxis of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Aspirin; Dose-Response Relationship, Drug; Hip Fractures; Humans; Pl | 2000 |
Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Aspirin; Cause of Death; Dose-Response Rela | 2000 |
[Possibilities and limits of controlled clinical therapy studies for the demonstration of the effectiveness of antithrombotic therapy].
Topics: Adult; Anticoagulants; Aspirin; Clinical Trials as Topic; Dextrans; Dipyridamole; Dose-Response Rela | 1975 |
Internation Committee on Thrombosis and Haemostasis Basil, 8.-11. September 1974 Subcommittee on Clinical Investigations: Registry of prospective clinical trials.
Topics: Ancrod; Animals; Arterial Occlusive Diseases; Aspirin; Batroxobin; Clinical Trials as Topic; Fibrino | 1975 |
Aspirin prophylaxis of venous thromboembolism after total hip replacement.
Topics: Adult; Aspirin; Clinical Trials as Topic; Female; Fibrinogen; Hip Joint; Humans; Joint Prosthesis; M | 1977 |
[Heparin in the prevention of thromboembolism after elective hip-joint operations (author's transl)].
Topics: Aspirin; Female; Germany, West; Heparin; Hip Joint; Humans; Male; Middle Aged; Postoperative Complic | 1978 |
Mechanism of action and clinical use of acetylsalicylic acid as a prophylactic agent against thrombosis.
Topics: Aspirin; Cardiac Surgical Procedures; Clinical Trials as Topic; Humans; Leg; Placebos; Platelet Aggr | 1975 |
[A randomized study on the prevention of postoperative thrombosis with acetylsalicylic acid].
Topics: Aspirin; Clinical Trials as Topic; Humans; Placebos; Postoperative Complications; Pulmonary Embolism | 1976 |
[Low-dose heparin and acetyl-salicylic acid after elective operations on the hip joint (author's transl)].
Topics: Aged; Aspirin; Female; Heparin; Hip Joint; Humans; Joint Prosthesis; Male; Middle Aged; Postoperativ | 1977 |
[Quantitative assessment of drug-induced prophylaxis of postoperative thromboembolism. Comparison of frequencies of deep vein thrombosis and pulmonary embolism using acetylsalicylic-acid, dextran, dihydroergotamine, low-dose heparin and the fixed combinat
Topics: Adult; Aged; Aspirin; Dextrans; Dihydroergotamine; Drug Therapy, Combination; Female; Heparin; Human | 1977 |
[Thrombosis, embolism and aggregation inhibitors in surgery].
Topics: Aged; Anticoagulants; Aspirin; Dipyridamole; Female; Humans; Male; Platelet Aggregation; Postoperati | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts).
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; Fibrin | 1975 |
Aspirin halves pulmonary embolism.
Topics: Aspirin; Humans; Postoperative Complications; Pulmonary Embolism | 1991 |
[Prevention of thromboembolism in para-articular femoral fractures of the hip--results of a prospective randomized study of heparin-DHE and ASS-DHE].
Topics: Aged; Aged, 80 and over; Aspirin; Bone Screws; Cause of Death; Dihydroergotamine; Drug Combinations; | 1990 |
Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis.
Topics: Adult; Aspirin; Clinical Trials as Topic; Clothing; Dextrans; Dihydroergotamine; Drug Combinations; | 1988 |
A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Female; Follow-Up Studies; Hemorr | 1989 |
Prevention of deep venous thrombosis in orthopedic surgery: effects of defibrotide.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Heparin; Hip Joint; Humans; Male; Orthopedics; Polydeoxy | 1988 |
Prevention of thromboembolism in total hip replacement. Aspirin versus dihydroergotamine-heparin.
Topics: Aspirin; Clinical Trials as Topic; Dihydroergotamine; Drug Combinations; Drug Therapy, Combination; | 1987 |
Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine.
Topics: Aspirin; Blood Platelet Disorders; Clinical Trials as Topic; Dihydroergotamine; Drug Combinations; H | 1986 |
[Thromboembolic complications following total hip prosthesis. Study of 478 cases of relative efficacy of 3 preventive methods].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Dextrans; Drug Evaluation; Drug Therapy, Combinat | 1974 |
Review of present status of prophylaxis of venous thromboembolism.
Topics: Adult; Aspirin; Clinical Trials as Topic; Dextrans; Dipyridamole; Fibrinolysis; Heparin; Humans; Phy | 1974 |
Reduction in venous thromboembolism by agents affecting platelet function.
Topics: Adult; Aged; Arthroplasty; Aspirin; Blood Platelets; Chromium Alloys; Dextrans; Dipyridamole; Female | 1971 |
223 other studies available for aspirin and Embolism, Pulmonary
| Article | Year |
|---|---|
Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.
Topics: Animals; Blood Coagulation; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Hemorrhage; Hu | 2016 |
Time to Venous Thromboembolism Events Following Total Hip Arthroplasty: A Comparison Between Aspirin and Warfarin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Pu | 2022 |
Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures?
Topics: Anticoagulants; Aspirin; Chemoprevention; Enoxaparin; Hematoma; Heparin; Hip Fractures; Humans; Pelv | 2022 |
Combined oral contraceptive-associated venous thromboembolism revealing an antiphospholipid syndrome: International retrospective study of outcomes.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Contraceptives, Or | 2022 |
Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Humans; Incidence; Male; Medicare; | 2023 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Thromboprophylaxis after Extremity Fracture - Time for Aspirin?
Topics: Anticoagulants; Aspirin; Chemoprevention; Extremities; Fractures, Bone; Humans; Pulmonary Embolism; | 2023 |
Trends of Venous Thromboembolism After Total Hip Arthroplasty in the United States: Analysis From 2011 to 2019.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Fibrinolytic Agents; Humans; Postoperative | 2023 |
Aspirin for Venous Thromboembolic Prophylaxis Following Total Hip and Total Knee Arthroplasty: An Analysis of Safety and Efficacy Accounting for Surgeon Selection Bias.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Pu | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture. Reply.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
The impact of adopting low-molecular-weight heparin in place of aspirin as routine thromboprophylaxis for patients with hip fracture.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Postoperative Complic | 2023 |
Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Humans; Postoperative Complicat | 2023 |
Prophylaxis for Pediatric Venous Thromboembolism: Current Status and Changes Across Pediatric Orthopaedic Society of North America From 2011.
Topics: Aspirin; Enoxaparin; Guideline Adherence; Humans; North America; Orthopedic Procedures; Pediatrics; | 2020 |
Incidence of venous thromboembolism after total hip, total knee and hip fracture surgery at Waitemata District Health Board following a peer-reviewed audit.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2020 |
Acetylsalicylic acid (Aspirin): a potent medicine for preventing COVID-19 deaths caused by thrombosis and pulmonary embolism.
Topics: Aspirin; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Platelet Aggregation | 2020 |
Discontinued Use of Outpatient Portable Intermittent Pneumatic Compression Devices May Be Safe for Venous Thromboembolism Prophylaxis in Primary Total Knee Arthroplasty Using Low-Dose Aspirin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; In | 2022 |
Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion; Hemorrhage; Humans; Met | 2020 |
Low-dose aspirin and the rate of symptomatic venous thromboembolic complications following primary shoulder arthroplasty.
Topics: Arthroplasty, Replacement, Shoulder; Aspirin; Humans; Incidence; Postoperative Complications; Pulmon | 2021 |
Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Antiviral Agents; Aspirin; Blood Platelets; Coronary | 2021 |
Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemokine CX3CL1; CX3C Che | 2017 |
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; D | 2017 |
Fatal pulmonary embolism following elective total knee replacement using aspirin in multi-modal prophylaxis - A 12year study.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Chemoprevention; Clinical Protocols; Combi | 2017 |
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Factor X | 2017 |
Wound Discharge After Pharmacological Thromboprophylaxis in Lower Limb Arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2018 |
Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Dose-Respo | 2018 |
The Role of Aspirin and Unfractionated Heparin Combination Therapy Immediately After Total Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Bloo | 2018 |
Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Electronic Health Records; Female; H | 2018 |
Evaluation of the antithrombotic activity of Zhi-Xiong Capsules, a Traditional Chinese Medicinal formula, via the pathway of anti-coagulation, anti-platelet activation and anti-fibrinolysis.
Topics: Acute Disease; Animals; Anticoagulants; Antithrombins; Aspirin; Blood Coagulation; Capsules; Carotid | 2018 |
Postpartum spontaneous renal blood vessel rupture followed by pulmonary artery thromboembolism associated with protein C deficiency.
Topics: Adult; Aspirin; Cesarean Section; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnanc | 2019 |
Reversible cerebral vasoconstriction complicating cerebral atherosclerotic vascular disease in Schimke immuno-osseous dysplasia.
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Carvedilol; Child; Clopidogrel; Diagnosis, Differential; | 2018 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conf | 2018 |
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
Topics: Anticoagulants; Aspirin; Cost Savings; Dose-Response Relationship, Drug; Drug Monitoring; Female; He | 2018 |
The Effectiveness of Aspirin for Venous Thromboembolism Prophylaxis for Patients Undergoing Arthroscopic Rotator Cuff Repair.
Topics: Adult; Aged; Aged, 80 and over; Arthroscopy; Aspirin; Case-Control Studies; Female; Humans; Male; Mi | 2019 |
Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Aspirin; Female; Huma | 2020 |
Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2019 |
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; | 2020 |
[Effects of aspirin on CX3CL1 and CX3CR1 in acute pulmonary embolism rats].
Topics: Animals; Aspirin; Chemokine CX3CL1; CX3C Chemokine Receptor 1; Lung; Pulmonary Embolism; Rats; Rats, | 2013 |
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
Topics: Acenocoumarol; Age Factors; Antineoplastic Agents; Aspirin; Female; Genetic Predisposition to Diseas | 2013 |
Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty?
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement; Aspirin; Female; Fibrinolytic Agents; Humans | 2014 |
Effects of aspirin on the ERK and PI3K/Akt signaling pathways in rats with acute pulmonary embolism.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blotting, West | 2013 |
Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Aspirin; Chi- | 2014 |
CORR Insights®: Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors.
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Pulmo | 2014 |
Statins, aspirin and risk of thromboembolic events in ovarian cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carcinoma, Ovarian Epithelial; | 2014 |
Screening for deep vein thrombosis after periacetabular osteotomy in adult patients: is it necessary?
Topics: Acetabulum; Adolescent; Adult; Age Factors; Aspirin; Female; Fibrinolytic Agents; Hip Dislocation, C | 2014 |
Letter to the editor: symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors.
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Pulmo | 2014 |
Reply to the letter to the editor: symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors.
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Pulmo | 2014 |
Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; APACHE; Aspirin; Clopidogrel; Female; Fibrin Fibrinogen Deg | 2014 |
Antithrombotic Activity of a New Hypoglycemic Compound Limiglidole in Mouse Model of Cell Thrombosis.
Topics: Animals; Arterioles; Aspirin; Benzimidazoles; Capillaries; Collagen; Drug Evaluation, Preclinical; E | 2015 |
Prevention of deep vein thrombosis. First choice treatments.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Early Ambulation; Heparin, Low-Molecular-Weight; | 2015 |
Duration of anticoagulation: the decision-making process.
Topics: Anticoagulants; Aspirin; Decision Making; Humans; Platelet Aggregation Inhibitors; Practice Guidelin | 2015 |
Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticoagulants; Aspirin; Drug Administration Schedule; Fem | 2016 |
Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Female; Fibrinolytic Age | 2015 |
The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspiri | 2016 |
Aspirin for thromboprophylaxis after primary lower limb arthroplasty: early thromboembolic events and 90 day mortality in 11,459 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2016 |
Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty; Aspirin; Blood Loss, Surgical; Cohort Studies; Female; | 2016 |
Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fema | 2016 |
Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Chemoprevention; Clinical Audit; Elec | 2016 |
A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Arachidonic Acid; Aspir | 2016 |
Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion | 2016 |
Repeated Thrombosis After Synthetic Cannabinoid Use.
Topics: Adult; Anticoagulants; Aspirin; Cannabinoids; Enoxaparin; Female; Humans; Infarction; Platelet Aggre | 2016 |
Acute pulmonary embolism with precordial T-wave inversion and negative D-dimer.
Topics: Aged; Angiography; Anticoagulants; Aspirin; Chest Pain; Diagnosis, Differential; Dyspnea; Electrocar | 2017 |
Aspirin, the Unsung Champion of Deep Venous Thrombosis Chemoprophylaxis: A Historical Perspective: Commentary on an article by Javad Parvizi, MD, FRCS, et al.: "Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembo
Topics: Anticoagulants; Arthroplasty; Aspirin; Chemoprevention; Humans; Pulmonary Embolism; Thromboembolism; | 2017 |
Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty.
Topics: Adult; Age Factors; Aged; Arthroplasty, Replacement, Hip; Asian People; Aspirin; Computed Tomography | 2017 |
Bumpy road to the diagnosis of polycythaemia vera.
Topics: Aged; Anticoagulants; Aspirin; Female; Humans; Phlebotomy; Polycythemia Vera; Pulmonary Embolism; Tr | 2017 |
Regional anesthesia, compression, and aspirin is the safest form of prophylaxis for hip and knee arthroplasty.
Topics: Anesthesia, Conduction; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Hu | 2008 |
Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty.
Topics: Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Male; Middle Aged; Postoperative Complicat | 2008 |
Thromboprophylaxis for patients at high risk of VTE.
Topics: Anticoagulants; Aspirin; Heparin; Hip Fractures; Humans; Practice Guidelines as Topic; Pulmonary Emb | 2008 |
[The efficacy of alteplase in pulmonary embolism treatment].
Topics: Adult; Aged; Aged, 80 and over; Angiography; Aspirin; Female; Fibrinolytic Agents; Heparin; Humans; | 2008 |
[Massive retroperitoneal hematoma during enoxaparin combined with aspirin treatment of acute pulmonary embolism: a case report].
Topics: Aged; Aspirin; Enoxaparin; Female; Hematoma; Humans; Pulmonary Embolism; Retroperitoneal Space | 2008 |
The use of aspirin with PC-SPES may not prevent pulmonary embolism.
Topics: Aged; Anticoagulants; Aspirin; Drugs, Chinese Herbal; Humans; Kallikreins; Male; Prostate-Specific A | 2003 |
Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Evidence-B | 2009 |
The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2009 |
Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients.
Topics: Anticoagulants; Aspirin; Female; Humans; Iatrogenic Disease; Incidence; Intermittent Pneumatic Compr | 2009 |
Venous thromboembolism debate in joint arthroplasty.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Re | 2009 |
Aspirin in the primary prevention of vascular disease.
Topics: Aspirin; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Ag | 2009 |
DVT prophylaxis: better living through chemistry: affirms.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Chemopreve | 2010 |
Pulmonary embolism prophylaxis in more than 30,000 total knee arthroplasty patients: is there a best choice?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin | 2012 |
Thromboembolic events are uncommon after open treatment of proximal humerus fractures using aspirin and compression devices.
Topics: Aspirin; Comorbidity; Early Ambulation; Female; Fracture Fixation, Internal; Humans; Incidence; Male | 2011 |
Dose-related effect of statins in venous thrombosis risk reduction.
Topics: Aged; Aspirin; Atherosclerosis; Cerebral Infarction; Clopidogrel; Cohort Studies; Cross-Sectional St | 2011 |
The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Drug Evaluation; England; Female; Hep | 2011 |
Incidence of venous thromboembolism in elective foot and ankle surgery with and without aspirin prophylaxis.
Topics: Ankle; Aspirin; Female; Foot; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Care; Pos | 2012 |
High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study.
Topics: Aged; Antibodies, Antiphospholipid; Aspirin; Biomarkers; Chronic Disease; Cross-Sectional Studies; E | 2012 |
Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Body Mass | 2012 |
Massive pulmonary thromboembolism after intravenous stroke thrombolysis.
Topics: Aged; Aspirin; Echocardiography; Female; Heparin, Low-Molecular-Weight; Humans; Infusions, Intraveno | 2012 |
Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement; Arthroplasty, Replacement, Hi | 2012 |
The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Drug Evaluation; Drug Utilization; E | 2012 |
Recurrent thromboembolism in a patient with beta-thalassemia major associated with double heterozygosity for factor V R506Q and prothrombin G20210A mutations.
Topics: 3' Untranslated Regions; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; beta-Thalas | 2002 |
Acute pulmonary embolism: don't ignore the platelet.
Topics: Acute Disease; Animals; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidog | 2002 |
Management of thrombosis during pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Aspirin; Blood Coagulation Tests; Drug The | 2002 |
'Coach class thrombosis': is the risk real? What do we tell our patients?
Topics: Aircraft; Aspirin; Bandages; Blood Viscosity; Contraindications; Heparin, Low-Molecular-Weight; Huma | 2002 |
Isolated internal jugular vein thrombosis: risk factors and natural history.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; | 2002 |
Going with the flow of anticoagulant therapy.
Topics: Anticoagulants; Aspirin; Dipyridamole; Heparin; Humans; Patient Education as Topic; Platelet Aggrega | 2003 |
Antiplatelet drugs.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2003 |
[Can acetylsalicylic acid be used for the treatment of venous diseases?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Platelet Aggregation Inhibitors; Pulmonary | 2003 |
NCX4016: a novel antithrombotic agent.
Topics: Animals; Aspirin; Blood Platelets; Disease Models, Animal; Fibrinolytic Agents; Humans; In Vitro Tec | 2003 |
The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Topics: Adenosine Diphosphate; Agammaglobulinaemia Tyrosine Kinase; Amides; Animals; Aspirin; Bleeding Time; | 2003 |
["Economy class syndrome" associated with diabetes and Graves disease].
Topics: Aged; Aircraft; Anticoagulants; Aspirin; Diabetes Complications; Female; Graves Disease; Humans; Pul | 2003 |
Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging.
Topics: Aged; Aspirin; Bandages; Female; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; Male; Pulm | 2004 |
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "grosso".
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Guinea Pigs; In Vitro Techn | 2004 |
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice.
Topics: Animals; Aspirin; Blood Coagulation Tests; Clopidogrel; Disease Models, Animal; Drug Therapy, Combin | 2005 |
Chest pain and arthritis.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspir | 2005 |
Deep venous thrombosis prophylaxis: better living through chemistry--in opposition.
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Humans; Postoperative Complications; Pulmonary E | 2005 |
Thromboembolic disease prophylaxis in total hip arthroplasty.
Topics: Arthroplasty, Replacement, Hip; Aspirin; California; Cause of Death; Evidence-Based Medicine; Exerci | 2005 |
Pulmonary embolism aggravated by two short flights 3 days apart.
Topics: Aerospace Medicine; Age Factors; Aged, 80 and over; Aircraft; Aspirin; Humans; Male; Pulmonary Embol | 2005 |
The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty.
Topics: Arthroplasty, Replacement, Knee; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Pulmonary Embol | 2006 |
[A case of acute exacerbation of chronic pulmonary thromboembolism with essential thrombocythemia during treatment for hemoptysis].
Topics: Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Chronic Disease; Female; Hemoptysis; Humans; Ox | 2006 |
Aspirin in the prevention and treatment of venous thromboembolism: a rebuttal.
Topics: Aspirin; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Pulmonary Embolism; Rese | 2007 |
Thromboprophylaxis after hip fracture: evaluation of 3 pharmacologic agents.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dextrans; Enoxaparin; Female; Fibrinolytic Agents; | 2007 |
Factors associated with thromboprophylaxis for orthopedic patients and their impact on outcome.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Huma | 2007 |
Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Aorta; Aspirin; Blood Coagulation; Collagen; Disease Mo | 2007 |
Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Clinical Protocols; Female; Humans; Inciden | 2007 |
Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2007 |
Real-time measurement of non-lethal platelet thromboembolic responses in the anaesthetized mouse.
Topics: Adenosine Diphosphate; Anesthesia; Animals; Aspirin; Blood Platelets; Collagen; Disease Models, Anim | 2008 |
[Antipyretic, antiedematous and analgetic effects of damascenin in comparison with acetylsalicylic acid and phenylbutazone].
Topics: Alkaloids; Animals; Aspirin; Behavior, Animal; Body Temperature; Edema; Formaldehyde; Furosemide; Gu | 1967 |
Postoperative venous thrombosis. Evaluation of five methods of treatment.
Topics: Adult; Age Factors; Aged; Aspirin; Clothing; Dextrans; Female; Fibrinogen; Heparin; Humans; Iodine R | 1981 |
[Prevention of deep vein thrombosis and pulmonary thromboembolism].
Topics: Anticoagulants; Aspirin; Constriction; Dextrans; Electric Stimulation Therapy; Heparin; Humans; Phys | 1981 |
[Fatal pulmonary embolism after hip surgery].
Topics: Aspirin; Bandages; Dextrans; Early Ambulation; Hip Joint; Humans; Postoperative Complications; Pulmo | 1982 |
Prevention of postoperative deep venous thrombosis and pulmonary emboli with combined modalities.
Topics: Adult; Aged; Aspirin; Clothing; Combined Modality Therapy; Dextrans; Heparin; Humans; Middle Aged; M | 1983 |
The effects of aspirin and methysergide on responses to clot-induced pulmonary embolism.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Pressure; Dinoprost; Drug Therapy, Comb | 1983 |
Effects of immune modulation on Dirofilaria immitis infection in the dog.
Topics: Animals; Arsenamide; Aspirin; Dirofilariasis; Dog Diseases; Dogs; Prednisolone; Pulmonary Embolism | 1984 |
An aspirin-prednisolone combination to modify postadulticide lung disease in heartworm-infected dogs.
Topics: Animals; Arsenamide; Aspirin; Dirofilariasis; Dog Diseases; Dogs; Drug Therapy, Combination; Granulo | 1984 |
Pharmacological control of platelet-vessel wall interactions in patients with chronic obstructive airway disease.
Topics: Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Hematopoiesis; Humans; Lung Diseases, Obstruc | 1984 |
The involvement of prostaglandins and thromboxanes in the response to pulmonary embolism in anaesthetized rabbits and isolated perfused lungs.
Topics: 6-Ketoprostaglandin F1 alpha; Anesthesia, General; Animals; Aspirin; Hypotension; Indomethacin; Lung | 1983 |
Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease.
Topics: Angiography; Aspirin; Humans; Lung; Platelet Function Tests; Pulmonary Embolism; Radioimmunoassay; T | 1984 |
Prophylaxis of venous thromboembolism: analysis of cost effectiveness.
Topics: Aspirin; Cost-Benefit Analysis; Dextrans; Heparin; Humans; Injections, Subcutaneous; Pulmonary Embol | 1980 |
Aspirin and prednisolone modification of postadulticide pulmonary arterial disease in heartworm-infected dogs: arteriographic study.
Topics: Animals; Arsenamide; Aspirin; Dirofilariasis; Dog Diseases; Dogs; Drug Therapy, Combination; Prednis | 1983 |
Pulmonary thromboembolism during therapy of dirofilariasis with thiacetarsamide: modification with aspirin or prednisolone.
Topics: Animals; Arsenamide; Arsenicals; Aspirin; Dirofilariasis; Dog Diseases; Dogs; Drug Interactions; Lun | 1983 |
Aspirin prophylaxis for pulmonary embolism following total hip arthroplasty. An incidence study.
Topics: Adolescent; Adult; Aged; Aspirin; Female; Hip Prosthesis; Humans; Lung; Male; Middle Aged; Postopera | 1982 |
The detection and prevention of pulmonary embolism in total hip replacement. A study comparing aspirin and low-dose warfarin.
Topics: Aspirin; Female; Hip Joint; Hip Prosthesis; Humans; Male; Middle Aged; Postoperative Complications; | 1982 |
The effects of aspirin and methysergide, singly and in combination, on systemic haemodynamic responses to pulmonary embolism.
Topics: Animals; Aorta; Aspirin; Blood Pressure; Drug Synergism; Heart Rate; Hemodynamics; Male; Methysergid | 1981 |
Current concepts review. The use of aspirin in thromboembolic disease.
Topics: Adult; Aspirin; Female; Hip Prosthesis; Humans; Male; Platelet Aggregation; Postoperative Complicati | 1980 |
Pulmonary thromboembolism. 2. New trends in prophylaxis and therapy.
Topics: Aspirin; Dipyridamole; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation; Pulmonary Embolis | 1980 |
Management of venous thromboembolism.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Fibrinolytic Agents; Heparin; Humans; Isometric | 1980 |
Antithrombotic therapy in coronary artery disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Fibrinolytic Agents; Humans; Myocardial | 1980 |
[Current aspects of postoperative thrombophlebitis and pulmonary artery thromboembolism].
Topics: Adult; Age Factors; Aspirin; Bandages; Dextrans; Heparin; Humans; Iodine Radioisotopes; Middle Aged; | 1994 |
Clinical efficacy of aspirin and dextran for thromboprophylaxis in geriatric hip fracture patients.
Topics: Aged; Aspirin; Dextrans; Female; Hip Fractures; Humans; Male; Prospective Studies; Pulmonary Embolis | 1993 |
Effect of beraprost sodium, a stable prostacyclin analogue, on pulmonary thromboembolism in mice.
Topics: Administration, Oral; Alprostadil; Animals; Aspirin; Bridged Bicyclo Compounds; Collagen; Diltiazem; | 1995 |
Antiplatelet prophylaxis. Combination treatment may cause bleeding.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Platelet Aggregation Inhibitors; Pulmonary Embo | 1994 |
Lethal pulmonary embolism in a patient with primary antiphospholipid syndrome and a vena caval filter.
Topics: Antiphospholipid Syndrome; Aspirin; Cholecystectomy; Fatal Outcome; Female; Heparin; Humans; Middle | 1994 |
Pneumatic compression or aspirin prophylaxis against thromboembolism in total hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Gravity Suits; Hip Prosthesis; Huma | 1996 |
Anti-inflammatory effects of beraprost sodium, a stable analogue of PGI2, and its mechanisms.
Topics: Alprostadil; Animals; Anti-Inflammatory Agents; Aspirin; Cell Membrane Permeability; Collagen; Dose- | 1997 |
The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Topics: Adenosine Triphosphate; Animals; Arachidonic Acid; Aspirin; Biphenyl Compounds; Blood Platelets; Gui | 1997 |
Thromboprophylaxis in elective orthopaedic surgery -- what is the purpose?
Topics: Anticoagulants; Aspirin; Bone and Bones; Chemoprevention; Elective Surgical Procedures; Femoral Neck | 1997 |
[Pulmonary embolism as one cause of death after spinal injury--the role of clexane].
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Male; Middle Aged; Poland; Pulmonary Embolism; | 1998 |
DVT prophylaxis options: facts & fictions.
Topics: Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Postoperative Com | 1998 |
Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty.
Topics: Arthroplasty, Replacement, Hip; Aspirin; Bandages; Exercise Therapy; Female; Humans; Male; Platelet | 1999 |
Venous thromboembolic disease after hybrid hip arthroplasty with negative duplex screening.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Bandages; Female; | 1999 |
Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Calcimycin; Calcium; Catechin; Collagen; Epi | 1999 |
Clinical assessment of vascular thrombosis using indium-111 platelet scintigraphy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis Obliterans; Aspirin; Blood Platelet | 2000 |
Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Disease Models | 2000 |
Can low-dose aspirin prevent thromboembolic phenomena in patients undergoing surgery for hip fracture or elective arthroplasty?
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Cause of Death; Double-Blind Method; Follow-Up S | 2000 |
Antithrombotic effect of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa, on platelet plug formation in in vivo experiments.
Topics: Adenosine Diphosphate; Alkaloids; Animals; Aspirin; Bleeding Time; Blood Pressure; Drugs, Chinese He | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aspirin; Blood Transfusion; Cause of Death; Humans; Platelet Aggregation Inhibitors; Postoperative H | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aspirin; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation I | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aspirin; Humans; Placebos; Platelet Aggregation Inhibitors; Pulmonary Embolism | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Meta-Analysis as | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Animals; Aspirin; Cause of Death; Cyclooxygenase Inhibitors; Disease Models, Animal; Humans; Platele | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aspirin; Bandages; Humans; Patient Care Planning; Physical Therapy Modalities; Placebos; Platelet Ag | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aspirin; Hip Fractures; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Pulmonary | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aged; Arthroplasty, Replacement, Hip; Aspirin; Hip Fractures; Humans; Male; Myocardial Infarction; P | 2000 |
Generalisations on benefits of aspirin are dangerous.
Topics: Aspirin; Fibrinolytic Agents; Humans; Premedication; Pulmonary Embolism | 2000 |
Aspirin for the treatment of pulmonary embolism: vasoconstriction versus physical obstruction.
Topics: Aspirin; Cause of Death; Humans; Platelet Aggregation Inhibitors; Pulmonary Embolism; Survival Rate; | 2000 |
Thromboprophylaxis--which treatment for which patient?
Topics: Arthroplasty, Replacement, Hip; Aspirin; Chemoprevention; Fibrinolytic Agents; Hip Fractures; Humans | 2000 |
Hormone therapy and risk for venous thromboembolism: comments and correction.
Topics: Aspirin; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Platelet Aggrega | 2001 |
Antithrombotic effects of tetramethylpyrazine in in vivo experiments.
Topics: Acute Disease; Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Blood Pressure; Drug Evaluati | 2001 |
Venous thromboembolism after acute stroke.
Topics: Acute Disease; Aspirin; Bandages; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibit | 2001 |
Thromboprophylaxis in an academic medical center.
Topics: Academic Medical Centers; Age Factors; Aged; Aspirin; Bandages; Female; Heparin; Humans; Incidence; | 2001 |
Prophylactic low-dose aspirin therapy in patients having hip-fracture surgery or elective arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Hip Fractu | 2001 |
Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Bandages; | 2001 |
Antithrombotic effect of PMC, a potent alpha-tocopherol analogue on platelet plug formation in vivo.
Topics: Adenosine Diphosphate; Animals; Antioxidants; Aspirin; Bleeding Time; Blood Pressure; Chromans; Fluo | 2002 |
[Drug-induced lung diseases].
Topics: Aspirin; Asthma; Bronchitis; Busulfan; Contraceptives, Oral, Hormonal; Dose-Response Relationship, D | 1979 |
Development and treatment of post-traumatic pulmonary platelet trapping.
Topics: Animals; Aspirin; Biopsy; Blood Cell Count; Blood Platelets; Chromium Radioisotopes; Dextrans; Disea | 1975 |
Pulmonary embolism prophylaxis in the orthopaedic and trauma patient.
Topics: Arthroplasty; Aspirin; Dextrans; Femoral Neck Fractures; Heparin; Hip Joint; Humans; Postoperative C | 1976 |
[Experience in the use of acetylsalicylic acid for prevention in traumatology. Report of 3-years experience].
Topics: Aged; Aspirin; Female; Femoral Fractures; Humans; Pulmonary Embolism; Thromboembolism | 1977 |
Effects of aspirin on vascular response to pulmonary embolism.
Topics: Animals; Aspirin; Blood Pressure; Male; Prostaglandins; Pulmonary Artery; Pulmonary Embolism; Rabbit | 1979 |
Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery.
Topics: Adult; Aged; Aspirin; Elasticity; Female; Humans; Knee; Leg; Male; Middle Aged; Phlebography; Pulmon | 1979 |
Pulmonary embolism in a homocystinuric patient during treatment with dipyridamole and acetylsalicylic acid.
Topics: Adolescent; Aspirin; Dipyridamole; Homocystinuria; Humans; Male; Pulmonary Embolism | 1978 |
[Pulmonary emboli during tropical pyomyositis. Proposal of a preventive treatment].
Topics: Adult; Aspirin; Democratic Republic of the Congo; Heparin; Humans; Myositis; Pulmonary Embolism | 1977 |
A multifaceted approach to prevention of thromboembolism: a report of 529 cases.
Topics: Aspirin; Bandages; Dextrans; Exercise Therapy; Heparin; Hip Joint; Humans; Joint Prosthesis; Phenylb | 1977 |
The prevention of acute pulmonary embolism.
Topics: Adult; Anticoagulants; Aspirin; Dextrans; Early Ambulation; Female; Heparin; Humans; Leg; Postoperat | 1977 |
Thromboembolism following total hip-replacement arthroplasty. The efficicy of dextran-aspirin and dextran-warfarin in prophylaxis.
Topics: Arthroplasty; Aspirin; Dextrans; Drug Therapy, Combination; Female; Hip Joint; Humans; Joint Prosthe | 1976 |
A clinical evaluation of aspirin prophylaxis of thromboembolic disease after total hip arthroplasty.
Topics: Adolescent; Adult; Aged; Arthroplasty; Aspirin; Female; Hip Joint; Humans; Joint Prosthesis; Male; M | 1976 |
[A comparative investigation of acetylsalicyclic acid and indirect anticoagulants for the prophylaxis of venous thromboses in patients with an orthopedic-traumatologic case history (author's transl)].
Topics: Aspirin; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteotomy; Phenindione; Postoperative C | 1976 |
Combined administration of low dose heparin and aspirin as prophylaxis of deep vein thrombosis after hip joint surgery.
Topics: Adult; Aged; Aspirin; Drug Therapy, Combination; Female; Heparin; Hip Joint; Humans; Male; Middle Ag | 1976 |
Patho-physiological studies on lactic acid-induced pulmonary thrombosis in rat. I. Effect of heparin, acetylsalicylic acid, urokinase and tranexamic acid.
Topics: Animals; Aspirin; Blood Coagulation; Disseminated Intravascular Coagulation; Fibrinolysis; Heparin; | 1975 |
Prophylaxis of venous thromboembolism.
Topics: Aspirin; Blood Coagulation; Dextrans; Dipyridamole; Ethylestrenol; Fibrinolysis; Heparin; Humans; Ph | 1975 |
Pulmonary damage following pulmonary microembolism in the dog. Effect of various types of treatment.
Topics: Animals; Aspirin; Calcium; Cyclohexanecarboxylic Acids; Dogs; Female; Indomethacin; Lung; Male; Meth | 1976 |
Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes.
Topics: Aspirin; Bandages; Hip Prosthesis; Humans; Knee Prosthesis; Postoperative Complications; Pulmonary E | 1992 |
The significance of calf thrombi after total knee arthroplasty.
Topics: Aspirin; Humans; Knee Prosthesis; Leg; Phlebography; Postoperative Complications; Pulmonary Embolism | 1992 |
Cyclooxygenase inhibition aggravates pulmonary hypertension and deteriorates gas exchange in canine pulmonary embolism.
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Dogs; Hypertension, Pulmonary; Indomethacin; Pulmonary | 1992 |
[Heparin-associated thrombocytopenia, thrombosis and embolism. Side effects of thromboembolism prevention with low molecular weight heparin enoxaparin?].
Topics: Aged; Aspirin; Blood Coagulation Tests; Carcinoma, Renal Cell; Heparin, Low-Molecular-Weight; Humans | 1991 |
Interactions of saruplase with acetylsalicylic acid, heparin, glyceryl trinitrate, tranexamic acid and aprotinin in a rabbit pulmonary thrombosis model.
Topics: Animals; Aprotinin; Aspirin; Heparin; Iodine Radioisotopes; Male; Nitroglycerin; Plasminogen Activat | 1990 |
Air travel, DVTs and pulmonary embolism.
Topics: Aircraft; Aspirin; Humans; Pulmonary Embolism; Thrombophlebitis; Travel | 1991 |
Experimental studies on the mechanism of reversible pressor response in pulmonary microembolism in the dog.
Topics: Animals; Aspirin; Blood Pressure; Dogs; Latex; Particle Size; Prostaglandins; Pulmonary Embolism; Va | 1991 |
Air travel, DVTs and pulmonary embolism.
Topics: Aircraft; Aspirin; Humans; Pulmonary Embolism; Thrombophlebitis; Travel | 1991 |
Aspirin prophylaxis and surveillance of pulmonary embolism and deep vein thrombosis in total hip arthroplasty.
Topics: Aspirin; Female; Hip Prosthesis; Humans; Lung; Male; Middle Aged; Postoperative Complications; Preme | 1990 |
The role of platelets in the reflex tachypnoeic response to miliary pulmonary embolism in anaesthetized rabbits.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood Pressure; Immune S | 1990 |
Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression.
Topics: Animals; Aspirin; Disease Models, Animal; Epoprostenol; Male; Mice; Phthalic Acids; Platelet Aggrega | 1990 |
Prophylaxis of venous thromboembolic disease following hip and knee surgery.
Topics: Anticoagulants; Aspirin; Combined Modality Therapy; Dextrans; Heparin; Hip; Humans; Knee; Leg; Posto | 1986 |
Prophylaxis of venous thromboembolism. An overview.
Topics: Abdomen; Anticoagulants; Aspirin; Combined Modality Therapy; Cost-Benefit Analysis; Dextrans; Drug T | 1986 |
[Venous diseases of the lower limbs and pulmonary embolism].
Topics: Adult; Aged; Ancrod; Anticoagulants; Aspirin; Female; Humans; Male; Pulmonary Embolism; Thrombophleb | 1988 |
[Mortality and morbidity of thromboembolism in drug prevention--5-year analysis].
Topics: Adenocarcinoma; Adult; Aspirin; Cesarean Section; Dihydroergotamine; Female; Genital Diseases, Femal | 1988 |
Successful pregnancy after pharmacologic suppression of a circulating anticoagulant in a woman with previous pregnancy losses and pulmonary emboli. A case report.
Topics: Adult; Aspirin; Blood Coagulation; Female; Humans; Immunoglobulins; Infant, Newborn; Partial Thrombo | 1987 |
Activity, air boots, and aspirin as thromboembolism prophylaxis in knee arthroplasty. A multiple regimen approach.
Topics: Adult; Aged; Aged, 80 and over; Arthritis; Aspirin; Clothing; Combined Modality Therapy; Female; Fol | 1987 |
[Thromboembolic disease and changes in coagulation after total hip arthroplasty. Effect of prophylaxis with acetylsalicylic acid or heparin-dihydroergotamine].
Topics: Aspirin; Blood Coagulation; Dihydroergotamine; Drug Combinations; Female; Heparin; Heparin, Low-Mole | 1986 |
Mediators of the anaphylactic reaction.
Topics: Anaphylaxis; Animals; Aorta; Aspirin; Bronchial Spasm; Guinea Pigs; Histamine Release; Immunity, Cel | 1971 |
Anticoagulants: a guide for practitioners.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Dicumarol; Disseminated Intravascular Coagulation; Electri | 1973 |
Lung disease caused by drugs.
Topics: Aspirin; Asthma; Contraceptives, Oral; Drug-Related Side Effects and Adverse Reactions; Eosinophilia | 1969 |
[Comparison of the prevention of thrombo-embolism by heparin and sintrom and by Macrodex and Colfarit in gynecologic surgery of the elderly (author's transl)].
Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Blood Coagulation Disorders; Dextrans; Drug Therapy, C | 1974 |
Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement.
Topics: Aspirin; Dextrans; Female; Hemorrhage; Heparin; Hip Joint; Humans; Injections, Subcutaneous; Joint P | 1974 |
[Postoperative thromboembolic complications].
Topics: Aspirin; Blood Coagulation Tests; Heparin; Humans; Injections, Subcutaneous; Postoperative Complicat | 1972 |
The treatment of pulmonary embolism.
Topics: Adult; Aspirin; Blood Coagulation Tests; Cholelithiasis; Diabetes Complications; Female; Heparin; Hu | 1973 |
Acute cerebral infarction. Evaluation and treatment.
Topics: Angiography; Anticoagulants; Aspirin; Blood Pressure Determination; Cerebrospinal Fluid; Cerebrovasc | 1973 |
[Prophylaxis of thrombo-embolic complications in major surgery of the hip joint. A comparative controlled study with subcutaneous calcium heparinate and acetylsalicylic acid (author's transl)].
Topics: Aspirin; Calcium; Heparin; Hip; Hip Joint; Humans; Injections, Subcutaneous; Joint Prosthesis; Posto | 1973 |
Prevention of pulmonary platelet trapping following trauma.
Topics: Animals; Aspirin; Dextrans; Dogs; Platelet Adhesiveness; Platelet Aggregation; Pulmonary Embolism; W | 1973 |
Postoperative deep vein thrombosis and pulmonary embolism: a selective review and personal viewpoint.
Topics: Adult; Age Factors; Aged; Aspirin; Clothing; Dextrans; Dipyridamole; Exercise Therapy; Heparin; Huma | 1974 |
[Aspirin in the treatment of amaurosis. Before or after?].
Topics: Aspirin; Blindness; Dextrans; Humans; Pulmonary Embolism; Thrombophlebitis | 1972 |
Thrombosis prevention.
Topics: Animals; Arteries; Arthroplasty; Aspirin; Blood Platelets; Dextrans; Dipyridamole; Hemorrhage; Hip; | 1971 |